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1 Introduction  
1.1 Renal transplantation (RTx)  
Renal transplantation (RTx) is the treatment of choice for many patients with end-stage 
renal disease since it provides lower mortality rates and better quality of life compared 
to the conventional hemodialysis (Tonelli et al., 2011). The first successful RTx was 
carried out in 1954 in Brigham hospital in Boston, USA by Murray and donor and 
recipient of the renal graft were identical twins (Merrill et al., 1956).  
Advanced surgical techniques, tissue typing and most importantly various 
immunosuppressive strategies over the past decades has led to increase in the number of 
transplants and improvement in transplantation outcomes. Nowadays, transplantation 
medicine is recognized to be part of the standard professional practice in developed 
countries (Neipp et al., 2009). According to the German Foundation for Organ 
Transplantation (Deutsche Stiftung Organtransplantation – DSO), an average of ten 
organs are transplanted every day in Germany.  
 
Figure 1: Dynamics of the Eurotransplant kidney transplant waiting list and transplants between 1969 and 
2014 (statistics of Eurotransplant Organization) 
1.2 Immunosuppressive drugs  
Transplantation of unrelated organs triggers immunological defense reaction, potentially 
resulting in rejection of the transplanted organ. Consequently, balanced suppression of 
the alloimmune response through the use of effective immunosuppressive protocols is 
an essential pre-requisite for successful organ transplantation.  
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Managing the host‟s immune response after organ transplantation has passed through 
many stages. Total body irradiation, corticosteroids and azathioprine were among the 
earliest immunosuppressive strategies used. However their use was complicated by 
considerable toxicity and high rejection rates. The first immunosuppressive protocol 
which showed reasonable results was a combination of azathioprine and steroids. This 
regimen resulted in a 1-year graft survival rate of around 50% and it was the dominant 
protocol for over 20 years. The introduction of cyclosporine A (CsA) in the early 1980s 
has opened a new avenue in the field of transplantation medicine with a 1-year graft 
survival of > 90% (Taylor et al., 2005).    
The discovery of CsA was followed by introduction of other efficacious agents and the 
number of immunosuppressive drugs increased rapidly over the last few decades. 
Currently, there are four main groups of drugs used as maintenance therapy after 
transplantation:  calcineurin inhibitors (CNIs) (CsA and tacrolimus [Tac]), mammalian 
target of rapamycin inhibitors (sirolimus (Sir) and everolimus (Evr)), antiproliferative 
agents (azathioprine [AZA] and mycophenolic acid [MPA]) and corticosteroids. 
Furthermore, there are several biologic agents available for the initial induction of 
immunosuppression; two of them are used widely, anti-thymocyte globulin or 
interleukin-2 receptor antibody (Kalluri and Hardinger, 2012).  
Modern immunosuppressive protocols after organ transplantation are based on the 
combination of drugs which target the immune response at different levels. The aim of 
such combinations is to increase the overall efficacy and decrease the toxicity of the 
individual agents. Whereas different centers adopt different strategies, the most widely 
accepted regimen comprises a combination of a CNI (CsA or Tac), and anti-
proliferative agent (MPA) or a mTOR inhibitor (Sir or Evr) with or without antibody 
induction and steroids (Halloran, 2004). 
1.2.1 Calcineurin inhibitors  
CNIs include CsA and Tac. Both drugs are used extensively in transplantation medicine 
and most immunosuppressive protocols contain one of these CNI.  
Despite the difference in chemical structure, both CsA and Tac target the same pathway 
(Figure 2) After entering the cell, they are complexed with an immunophilin. CsA binds 
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to cyclophilin while Tac forms a complex with the immunophilin known as FK binding 
protein-12 (FKBP-12). The drug-immunophilin complex binds to calcineurin inhibiting 
its phosphatase activity which in turn prevents the dephosphorylation of the 
transcription factor nuclear factor of activated T-cells (NFAT) impeding its 
translocation to the nucleus and subsequent down-regulation of critical cytokine genes 
(Ho et al., 1996). Three genes were found to be mainly down-regulated, namely IL-2, 
IFN-γ and GM-CSF. The end-result is decreased activation of T-lymphocytes (Giese et 
al., 2004). 
 
 
 
Figure 2: Mechanism of action of CNIs; CsA = cyclosporine A; CyP = cyclophilin; FKBP= FK506 
binding protein; GM-CSF = granulocyte macrophage colony-stimulating factor; IFN- γ =interferon 
gamma; IL-2 = interleukin 2; NFAT = nuclear factor of activated T-cells; Tac = tacrolimus 
 
 
The prolonged use of CNIs is associated with chronic suppression of the immune 
system with an increased risk for malignancy and infections. In addition, CNIs have a 
wide range of drug-specific adverse effects; many of them are dose-dependent. The 
most important adverse effect of both Tac and CsA is nephrotoxicity. Furthermore, CsA 
therapy is associated with increased incidence of hypertension, hyperlipidemia, 
hirsutism and gingival hyperplasia, while Tac therapy is associated more with the 
incidence of neurotoxicity, post-transplant diabetes mellitus and alopecia. However, the 
toxic profile of both drugs is overlapping (Taylor et al., 2005).  
   
CNIs are characterized by a highly variable pharmacokinetic (PK) profile among 
individuals. The oral bioavailability of CsA and Tac is irregular and difficult to predict. 
The peak level in the blood is reached during the first 2 to 3 hours after the dose which 
is the time of maximal calcineurin inhibition. CNIs are metabolized by the cytochrome 
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P450 isoenzymes (mainly CYP3A4 and CYP3A5) in the gut and liver. They are also 
substrate for P-glycoprotein which acts as an efflux pump transporting the drug out of 
the intestinal or hepatic cells (Kapturczak et al., 2004). 
 
1.2.2 mTOR inhibitors 
The mammalian target of rapamycin inhibitors (mTORIs) include Sir (known also as 
rapamycin) and Evr. These agents are used as alternative to CNIs in some patients 
particularly to decrease the risk of CNI-associated nephrotoxicity. They act by 
inhibiting the downstream signaling effects of the protein kinase mTOR which is a key 
regulator of cell growth and proliferation. After entering the cell, Sir and Evr bind to the 
FKBP-12 which acts as the drug receptor. The resulting complex binds to mTOR 
causing inhibition of its kinase activity with subsequent inhibition of cell proliferation. 
Their favorable effect as immunosuppressant comes from their ability to block 
cytokine-mediated T-cell proliferation (Dowling et al. 2010). 
 
The toxic profile of both Sir and Evr is similar and the adverse effects mostly comprise 
skin-, blood- and metabolism-related side effects. Anemia, leucopenia, 
thrombocytopenia, hyperlipidemia, skin rashes and mouth ulcers are among the most 
common adverse effects of both drugs (Taylor et al., 2005).  
 
Similar to the CNIs, the PK profile of mTORIs is also variable among individuals. 
While Sir is a naturally occurring compound, Evr was produced as a chemical 
modification of Sir by adding a hydoxyethyl group at position 40 of Sir. This 
modification resulted in differences in the PK properties. Evr is much more polar than 
Sir with a subsequent difference in tissue distribution. The elimination half life of Evr is 
also considerably lower than that of Sir (mean 28 h vs. 62 h in mean). Both drugs are 
metabolized by the CYP3A enzyme system (Klawitter et al., 2015). 
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1.3 Monitoring of therapy with immunosuppressive drugs 
1.3.1 The pharmacokinetic approach 
The immunosuppressive drugs are characterized by having a narrow therapeutic 
window. Thus monitoring of the therapy is mandatory to keep the delicate balance 
between over-immunosuppression with increased risk of infection or malignancy and 
under-immunosuppression with increased the risk of rejection. The therapy with 
immunosuppressive drugs is further complicated by the great interindividual variability 
of pharmacokinetics which makes the “one dose fits all” strategy unsuitable for these 
drugs.  
 
These facts constitute the rational of the traditional therapeutic drug monitoring (TDM) 
which is the currently used approach to guide dosing of the immunosuppressive drugs. 
TDM entails the use of the level of the drug in the blood or plasma, mostly the pre-dose 
level to adjust the dose of drug with the aim of keeping the drug level within a 
predefined therapeutic range (Cattaneo et al., 2004). 
 
The use of TDM as a tool to adjust therapy with immunosuppressive drugs allowed 
reducing the PK component of variability of drug response. This approach has, 
however, several shortcomings: a) TDM is applied only when therapy has been started 
so it cannot be used to predict the initial dose, b) It does not account for the inter-
individual variability in the immune response i.e. the PD component, and c) It is of less 
value to predict the response in case of multiple drug therapy with possible interaction 
(Budde and Glander, 2005). 
 
All these limitations reveal the need to search for new approaches to help a better 
optimization of the therapy with the immunosuppressive drugs. 
1.3.2 Pharmacodynamic Biomarkers 
Owing to the great variability in response of patients to immunosuppressive drugs and 
the incompetence of the conventional approaches to account for such variability, the 
trend in the field of transplantation medicine is moving toward a more tailored approach 
or “individualized therapy”. This approach is strongly linked to the development of 
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“biomarkers” which could reflect the individual response of the patients to the drug 
therapy (Ashton-Chess et al., 2009). 
 
According to the Biomarkers Definitions Working Group of the NIH, a biological 
biomarker can be defined as: “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention” (Strimbu and Tavel, 2010). 
There are different kinds of biomarkers which could be employed as predictors of the 
patient‟s response to treatment; pharmacodynamic (PD) and pharmacogenetic (PGx) 
biomarkers are among the most notable biomarker categories. While PD biomarkers are 
concerned with measurement of the physiologic effect of the immunosuppressive drugs 
on their targets, the PGx biomarkers investigate the effect of genetic variation on 
response to drugs including adverse drug reactions. 
 
A wide range of PD biomarkers for immunosuppressive drugs have been proposed in 
the last decade indicating the general effect of the drug on the immune cells or more 
specific indicating the direct effect of the drug on specific drug targets (Wieland et al., 
2010). However, only a very limited number of these biomarkers are currently accepted 
in clinical practice. This is because most of the biomarkers are neither analytically 
validated according to international guidelines nor suitable due to their complicated 
nature for routine use. From this perspective more efforts need to be spent to test the 
“fitness for purpose” of the candidate biomarker assays which has the potential to be 
implemented clinically.  
 
Therefore, the analytical performance of two PD assays was tested in the current thesis: 
the first assay is related to the monitoring of CNI therapy and is based on the 
determination of variable expression levels of certain cytokine genes under the 
influence of CNIs (NFAT-regulated gene expression assay). The second assay monitors 
mTORI therapy and is based on measuring the various level of phosphorylation of a 
ribosomal protein that is decreased under the influence of mTORIs therapy 
(measurement of S6RP using phosphoflow).  
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A) NFAT-regulated gene expression assay  
As stated before (section 1.2.1.), CNIs impede the action of the transcription factor 
NFAT and consequently down-regulate certain target genes (IL2-, IFN-γ and GM-CSF). 
Giese and colleagues (Giese et al., 2004) have established a method to estimate the 
residual transcriptional activity of NFAT through measuring the level of gene 
expression of IL-2, INF-γ and GM-CSF in mitogen stimulated whole blood at two 
different time points (before and after drug intake) using reverse transcription–qPCR 
(RT-qPCR). The extent to which the expression of these genes is inhibited after intake 
of CsA or Tac reflects the degree of immunosuppression exerted by these agents. This 
method could be used in addition to TDM to monitor CNI therapy particularly in long-
term renal allograft recipients. The assay protocol has been established in the Institute of 
Immunology at the University of Heidelberg and a primer set for the amplification of 
the target genes is commercially available (Search-LC, Heidelberg).  
 
The NFAT-regulated gene expression assay which utilizes RT-qPCR provides several 
advantages: a) The results are available within 24 hours; b) No sophisticated cell 
isolation and incubation steps are needed; c) A primer set for the amplification of the 
target genes is commercially available; d) The assay protocol is clearly described; and 
e) There are promising data from clinical trials including de novo and stable transplant 
patients (Sommerer et al., 2012). 
 
These data indicate that the NFAT-regulated gene expression assay is a promising PD 
biomarker assay that has the potential to be implemented clinically. However, data 
about the performance of this assay in an independent laboratory as well as data about 
inter-laboratory performance are, so far, lacking. In this work, the analytical 
performance of the NFAT-regulated gene expression assay was tested in the clinical 
laboratory of the Klinikum Stuttgart, Germany utilizing the commercially-available kit 
(Cyclosporine Immune Monitoring; Search-LC, Heidelberg). Furthermore an 
interlaboratory comparison with University Hospital Heidelberg was performed to 
ensure agreement of the results.  
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B) Measuring the level of S6RP through phosphoflow  
mTOR is a serine/threonine kinase, which operates through phosphorylation of serine 
and threonine residues at downstream target molecules (Figure 3). One of its most 
notable targets is p70 ribosomal protein S6 kinase 1 (p70S6K), leading to its activation. 
The p70S6 kinase is in turn another protein kinase which, upon activation by mTOR, 
phosphorylates also downstream targets as the 40S ribosomal protein S6 (S6RP) that is 
involved in regulation of protein translation (Asnaghi et al., 2004). Inhibition of mTOR 
through the action of mTORIs leads to decreased level of phosphorylation of its 
downstream targets whether direct or indirect (Dowling et al., 2010). Therefore 
measurement of the level of phosphorylation of these molecules could be used as a 
biomarker of therapy with mTORIs. 
 
Figure 3: The mTOR pathway; the main upstream effector of mTOR is the PI3K-Akt pathway which 
responds to wide variety of signals including growth factors. mTOR is a protein kinase which 
phosphorylates p70S6K1which in turn phosphorylates S6RP.. mTOR inhibitors decrease the level of 
phosphorylation of p70S6K1 as well as S6RP through inhibiting mTOR. Akt = protein kinase B; GF = 
growth factor; mTOR = mammalian target of rapamycin p70S6K1 = 70kDa ribosomal protein S6 
Kinase1; PI3K = phosphoinositide 3-kinase; S6RP = S6 ribosomal protein 
 
Several research groups have addressed the use of the phosphorylation status of p70S6 
kinase and its substrate S6RP as biomarkers of mTORI therapy. Different approaches 
have been attempted: western blot assay (Hartmann et al., 2005) and ELISA (Dekter 
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et al., 2010; Hartmann et al., 2013). However, these protocols are not suitable for 
routine clinical use since they entail the use of peripheral blood mononuclear cells 
(PBMCs) as a sample matrix which requires a long preparation time and the use of large 
sample volume in addition to the complicated nature of the assay protocol. 
The use of flow cytometry provides many advantages over the other traditional 
analytical techniques since it is rapid, sensitive and high throughput. Therefore, the use 
of flow cytometry in the clinical laboratory showed remarkable increase in the last 
decade. The advent of antibodies against phosphoproteins turned the phosphoflow 
technique into a powerful tool for analysis of cell signaling events (phosphoflow 
technique).  
Previous work showed the possibility to measure the level of p70S6K in the context of 
PBMCs with satisfactory analytical performance using phosphoflow technique 
(Hoerning et al., 2015; Wang and Fan, 2015). Despite the promising results of the use 
of phosphoflow as a measure of phosphorylation status of mTOR targets, these 
protocols employ the use of PBMCs as well, which render them not appropriate for the 
clinical setting   
The use of whole blood samples would, therefore, represents a better alternative when it 
comes to the routine clinical practice. Previously, this would be confronted with the 
artifactual changes that occur during sample processing since protein phosphorylation is 
highly dynamic. This hurdle has been overcome by the introduction of a protocol that 
entails fixation of the leucocytes in whole blood samples before lysis of red blood cells 
(RBCs) (Chow et al., 2005). This concept was first addressed by Dieterlen et al. who 
established a phosphoflow protocol to measure the level of phosphorylation of S6RP 
using whole blood as a sample matrix. The assay showed satisfactory analytical 
performance in vitro (Dieterlen et al., 2012). However, there are so far no published 
data regarding the performance of the assay using clinical patient samples. Furthermore, 
the fixation-permeabilization steps were conducted employing an in-house established 
protocol. Replication of the results in absence of an optimized commercial kit is 
difficult.  
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In this work, the technique of phosphoflow was used to measure the level of 
phosphorylation of S6RP using whole blood samples as a biomarker for mTOR 
inhibitors‟ activity. The assay protocol was set up in the Central Institute for Clinical 
Chemistry and Laboratory Medicine, Klinikum Stuttgart and entails the use of a 
commercial kit (PerFix-p Kit, Beckman Coulter) to fix and permeabilize white blood 
cells (WBCs) in whole blood samples before lysis of RBCs and anti-human p-S6RP 
(S235/S236) as a phosphoantibody. The analytical performance of the assay protocol 
was then tested both in vitro using blood samples spiked with different 
immunosuppressive drugs and ex vivo with residual clinical samples of different patient 
groups and three volunteers who took a single dose of Evr. In a separate set of 
experiments and to verify the measured values with a conventional method, the results 
of phosphoflow cytometry were compared with western blot technique.  
1.3.3 Pharmacogenetic biomarkers 
The variability of response to drugs among individuals is multifactorial. One important 
factor is the difference in the genetic make-up of the patients. It has been shown that 
genetic variation can be responsible for up to 60% of interindividual variability of drug 
response including genes coding for drug targets, drug metabolizing enzymes and drug 
transporters (Godman et al., 2013).  
Pharmacogenetics and pharmacogenomics aim to elucidate underlying mechanisms for 
inter-individual variability in drug response with specific focus on genetic variation. 
While pharmacogenetics refers to the effect of a single gene on the response to a drug, 
pharmacogenomics is a broader term which refers to the impact of the genome as a 
whole on the response of a drug. Nevertheless, the two terms are used interchangeably 
(Yagil and Yagil, 2002).     
Genetic variants which are found in > 1% of a population are termed genetic 
polymorphisms. The most common type of polymorphisms is the single nucleotide 
polymorphism (SNP) which refers to a single nucleotide alteration in a certain DNA 
sequence. The impact of genetic polymorphisms on immunosuppressive drug therapy 
can be well illustrated by azathioprine which is among the earliest immunosuppressive 
drugs used after organ transplantation. Azathioprine is a purine analogue which is 
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inactivated by methylation through the action of the enzyme thiopurine 
methyltransferase (TPMT). Patients who carry a variant allele of TPMT (with 
consequent impaired ability to deactivate the drug) may be at increased risk of severe 
drug toxicity if a prior dose adjustment was not performed (de Jonge and Kuypers, 
2008). 
Genetic variation can also contribute significantly to the inter-individual variability in 
disposition and response to other immunosuppressive drugs like the widely used CNIs. 
Several SNPs in drug metabolizing enzymes and transporting proteins of CNIs have 
been described to date and which could impact CNI pharmacokinetics (Hasselink et al., 
2014).  In this work, the pharmacogenetic part focused on Tac since it is the standard 
CNI used after renal transplantation in the Klinikum Stuttgart.  
As Tac is metabolized by CYP3A4 and CYP3A5 isoenzymes and is substrate for P-
glycoprotein, genetic variations in these genes could be a significant determinant of 
inter-individual variability in PK of Tac. Except for the CYP3A5*3 polymorphism, the 
effects of other SNPs were inconsistent (Table 1 and 2). A special concern is the newly 
discovered CYP3A4*22 polymorphism which was found to have a minor allele 
frequency of 5-7% in Caucasians and to impact the PK of CNIs (Elens et al., 2013b). 
However, more evidence needs to be accumulated to validate the role of this SNP 
related to Tac PK . Similarly, numerous SNPs have been described for the ABCB1 gene 
encoding for P-glycoprotein, however only three of them were particularly of interest 
regarding Tac PK namely the variants 3435T>C, 2677T>G/A and 1236T>C SNPs. 
Many studies have addressed the influence of these individual SNPs or the specific 
haplotype T-T-T on the PK of CNIs (Table 3) 
In the PGx part of this thesis, the influence of seven SNPs in CYP3A4/5 and ABCB1 on 
Tac pharmacokinetics were investigated in a cohort of 121 renal transplant patients in 
the early period after transplantation. The investigated alleles are CYP3A5*3, 
CYP3A4*22, CYP3A4*1B, and four SNPs in the ABCB1 gene (3435T>C, 2677T>G/A 
and 1236T>C). 
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Table 1: Effect of CYP3A4*22 single nucleotide polymorphism on Tac pharmacokinetics after organ transplantation  
SNP 
Cohort 
Pharmacokinetic 
Parameter(s) 
Time point Outcome Ref. 
Patients 
Place of 
study 
n 
CYP3A4*22 RTx France  186 Tac trough level (C0) 
Dose-adjusted C0 
Tac dose- 
requirement 
 
Days 10, 14, 30, 60 and 90 
post-transplantation.  
 
N.B. Day 10 postoperative 
is  equivalent to day 3 after 
initial dose of Tac which is 
started at day 7 
postoperative 
Tac C0 was higher in carriers of CYP3A4*22 
compared to homozygous wild type at day 10 
postoperative (P< 0.001). 
 
Compared to the homozygous wild type, carriers of 
CYP3A4*22 showed higher dose-adjusted C0 of Tac 
as well as lower Tac dose requirement (by about 
30%) over time in the first 3 months after surgery  
Pallet et al., 
2015 
CYP3A4*22 RTx Belgium 96 Tac C0 
Dose-adjusted C0 
Tac dose- 
requirement 
First 2 weeks post-
operative  
During the first 2 weeks after transplantation, carriers 
of CYP3A4*22 showed higher Tac C0 (significant at 
days 2 and 10), higher dose-adjusted C0 (significant 
at days 2,3 and 10) and lower Tac doses (significant 
at days 3,4 and 14) 
Elens et al., 
2013a 
CYP3A4*22 
 
 
 
RTx Netherlands  
Belgium  
185 Tac C0 
Tac dose- 
requirement 
Day 3, day 10 and month1, 
3, 6 and 12 after 
transplantation  
 
N.B. Tac was administered 
2 days before surgery  
At day 3, Tac C0 was significantly higher in carriers 
of CYP3A4*22. This difference was not translated to 
a clinical relevance regarding the incidence of DGF   
From day 10 to month 6, the Tac dose requirement 
was found to be 33% lower in carriers of CYP3A4*22   
Elens et al., 
2011a 
CYP3A4*22 
 
RTx Netherlands  
 
49 Tac C0 
Dose-adjusted C0 
Tac dose- 
requirement 
 Patients in the stable 
phase (> 1 year after 
transplantation) 
CYP3A4*22 was associated with a significant 
increase in dose-adjusted C0 as well as a significant 
decrease in dose requirements 
Elens et al., 
2011b 
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CYP3A4*22 
 
RTx Poland 241 Tac C0  
Dose-adjusted C0 
Tac dose- 
requirement 
Day 7 and at month 1, 3, 6 
and 12 after transplantation 
Carriers of CYP3A4*22 showed a trend to exhibit 
higher Tac C0 and dose-adjusted C0, however the 
difference was significant only at month 3 (dose-
adjusted C0) and month 6 (C0) after transplantation 
Kurzawski et 
al., 2014 
CYP3A4*22 
 
RTx Norway 123 Dose-adjusted C0 
 
2 to 7 weeks after 
transplantation  
No difference was noticed regarding the dose-
adjusted C0 between carriers CYP3A4*22 and the 
wild type homozygote  
Lunde et al., 
2014 
CYP3A4*22 
 
RTx Netherlands  
 
101 Population PK 
analysis 
 CYP3A4*22 was associated with 16% lower 
clearance of Tac , however this effect was regarded to 
be clinically insignificant 
Moes et al., 
2014 
CYP3A4*22 
 
RTx Spain 206 Tac C0 
Dose-adjusted C0 
Tac dose- 
requirement 
1 Week 
6 Months 
Carriers of CYP3A4*22 did NOT show significance 
difference compared to the wild type homozygote 
regarding the Tac C0, dose-adjusted C0 and dose 
requirements at the selected time points 
Tavira et al., 
2013 
CYP3A4*22 
 
RTx Brazil  140 Dose-adjusted C0 
 
3 months after 
transplantation   
CYP3A4*22 was found to have No association with 
the dose-adjusted Tac  blood concentration at the 
examined time point   
Santoro et al., 
2013 
CYP3A4*22 
 
Pediatric 
heart Tx 
Netherlands 
(cohort form 
Canada) 
 
60  Tac C0  
Dose-adjusted C0 
Tac dose- 
requirement 
First 2 weeks after 
transplantation  
Tac dose requirements were 30% lower in carriers of 
CYP3A4*22 during the first 2 weeks after surgery, 
however No significant difference was seen 
regarding Tac trough level or dose-adjusted 
concentration in the same period.  
Gijsen et al., 
2013 
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Table 2: Effect of CYP3A5* single nucleotide polymorphism on Tac pharmacokinetics after renal transplantation  
Cohort 
Time point after 
transplantation  
Findings  
 
Described as the change in pharmacokinetics 
parameter between the expressers (who express at least 
allele; *1) and non-expressers (CYP3A5*3/*3)  
Ref.  
Type  
of Tx 
Place of 
study 
Number of 
study 
population 
Percentage of non-
expressers 
(CYP3A5*3/*3) within 
the study population 
RTx Netherlands 64 70% Months 3, 12 
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration 
Hesselink et al., 
2003 
RTx France  80 84% Month 1 
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration  
Thervet et al., 
2003 
RTx Belgium  50 78% Stable phase 
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration  
Haufroid et al., 
2004 
RTx Japan  30 57% Day 28 
↓ dose-adjusted C0 of Tac 
↓ dose-adjusted AUC0-12 of Tac 
↑ Tac dose requirements to reach target concentration 
Tsuchiya et al., 
2004 
RTx UK 180 69% Month 3 
↓ dose-adjusted C0 of Tac 
Longer time to reach target concentration  
Macphee et al., 
2005 
RTx China  118 59% 
Week 1 
Month 1, 3 
↓ dose-adjusted C0 of Tac 
Zhang et al., 
2005 
RTx China  30 63% Month 3,6, 12 ↓ dose-adjusted C0 of Tac Zhao et al., 2005 
RTx Canada 44 84% 
Week 1 
Month 3 
↓ dose-adjusted C0 of Tac 
Longer time to reach target concentration 
Roy et al., 2006  
RTx Germany 134 87% 
Stable phase   
(> one year post-
transplantation) 
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration 
Renders et al., 
2007 
RTx China 63 57% Day 28 
↑ Tac clearance 
↓ dose-adjusted AUC0-12 of Tac 
Rong et al., 2010 
RTx Brazil  151 61% 
Week 1 
Month 1, 2 and 3 
↓ dose-adjusted C0 of Tac 
Santoro et al., 
2011 
RTx France  209 82% 
Days 15, 30, 90  
Years 1, 2  
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration 
Glowacki et al., 
2011 
RTx Spain  103 90% Week 1 ↓ dose-adjusted C0 of Tac Gervasini et al., 
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Months 1, 5 
Year 1 
↑ Tac dose requirements to reach target concentration 2012 
RTx Morocco  10 60% 
First 3 month after 
transplantation  
↑ Tac dose requirements to reach target concentration 
Elmachad et al., 
2012 
RTx Mexico  
291 
124 adults 
167 pediatric 
52% Month 6 ↑ Tac dose requirements to reach target concentration 
García-Roca et 
al., 2012 
RTx Japan 39 56% Day 28 
↑ Tac clearance 
↓ dose-adjusted AUC0-12 of Tac 
↑ Tac dose requirements to reach target concentration 
Tada et al., 2005 
RTx Belgium  59 83% After first Tac dose 
↓ dose-adjusted C0 of Tac  
↓ weight-adjusted C0 of Tac 
Mourad et al., 
2006 
RTx Korea 70 63% Months 1, 3, 6, 12 
↓ dose-adjusted C0 of Tac 
↑ Tac dose requirements to reach target concentration 
Cho et al., 2012 
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Table 3: Effect of ABCB1 SNPS and haplotypes on Tac pharmacokinetics after organ transplantation  
Cohort 
SNPs investigated Time point Findings 
Ref. 
Transplant  Place  n 
RTx France  81 1236C>T, 2677G>T/A, 
3435C>T and haplotypes 
Month 1 2677GG:  C0/D 
C-G-C haplotype:  C0/D 
Anglicheau et al., 2003 
Liver Tx France  42 3435C>T 1-3 days post-
transplantation  
3435TT:  C0/D Bonhomme-Faivre et 
al., 2009 
Liver Tx Belgium 150  1236C>T, 2677G>T/A, 
3435C>T 
Day 7 1236CC, 2677GG:  Tac hepatic conc.  Elens et al., 2007  
RTx UK 206 1236C>T, 2677G>T/A, 
3435C>T and haplotypes 
Month 3 2677GG, 3435CC:  C0/D Fredericks et al., 2006 
Liver Tx 
Paediatric   
UK 51  1236C>T, 2677G>T/A, 
3435C>T and haplotypes  
Month 6  
Year 1,2,3,4,5  
Carriers of 2677G>T or 3435C>T:  C0/D only 3 
years post-transplantation  
T-T-T haplotype:  C0/D  
Hawwa et al., 2009 
RTx Spain  35 2677G>T/A, 3435C>T First 6 weeks after 
transplantation 
3435CC:  C0/D López-Montenegro et 
al., 2010 
RTx UK 180  3435C>T Month 3 3435CC:  C0/D MacPhee et al., 2002 
Liver/Renal  
Tx 
Italy 101  
Liver 50 
Renal 51 
2677G>T/A, 3435C>T Month 1,3,6 Carriers of 2677T/A:  dose requirements only in 
RTx recipients   
Provenzani et al., 2010 
RTx Canada 44 2677G>T/A, 3435C>T, T-
129C 
Week 1 
Month 3 
Less than three copies of T-129C, 2677T, 3435T:  
C0/D 
Roy et al., 2006 
Lung Tx USA 91 1236C>T, 2677G>T/A, 
3435C>T and haplotypes 
Month 1,3,6,9,12 1236TT/2677TT/3435TT:  C0/D Wang et al., 2006 
Liver Tx China  50 Tx 
50 donors 
3435C>T First month after 
transplantation  
3435CC:  Tac dose requirements  Wei-lin et al., 2006 
RTx Korea 70 1236C>T, 2677G>T/A, 
3435C>T and haplotypes 
Month 1,3,6,12 No association between ABCB1 polymorphisms and 
Tac concentrations 
Cho et al., 2012 
RTx Spain  103  1236C>T, 2677G>T/A, 
3435C>T and haplotypes 
Week 1 
Month 1,5,12 
No association between ABCB1 polymorphisms and 
Tac concentrations or dose requirements.  
Gervasini et al., 2012 
Liver/Renal  
Tx and liver 
donors 
Korea 506 Tx  
62 donors 
2677G>T/A, 3435C>T when conc. of Tac 
in blood level 
reached steady state 
No association between ABCB1 polymorphisms and 
Tac concentrations 
Jun et al., 2009 
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RTx Belgium 304 2677G>T/A, 3435C>T Month 3,12 No association between ABCB1 polymorphisms and 
Tac concentrations or dose requirements. 
Kuypers et al., 2010b 
RTx 
candidates 
Belgium  19 1236C>T, 2677G>T/A, 
3435C>T 
After the first dose 
of Tac  
No association between ABCB1 polymorphisms and 
Tac PK parameters 
Haufroid et al., 2006 
RTx Belgium  59  1236C>T, 2677G>T/A, 
3435C>T 
After the first dose 
of Tac ? 
No association between ABCB1 polymorphisms and 
Tac concentrations 
Mourad et al., 2006 
RTx Japan  39  3435C>T Day 28  No association between ABCB1 polymorphisms and 
Tac PK parameters 
Tada et al., 2005 
 
 
 
 
 
Aims of the thesis 
 
18 
 
2 Aims of the thesis: 
The aim of this thesis was to investigate PD and PGx biomarkers which may have the 
potential to be implemented in the clinical practice for better individualization of 
immunosuppressive therapy after renal transplantation. The following work is to be 
performed:  
1. Validation of the “NFTA-regulated gene expression assay” as a pharmacodynamic 
biomarker to monitor therapy with CNIs in an independent laboratory as well as 
testing its inter-laboratory performance  
2. Testing the analytical suitability of a phosphoflow assay protocol based on a 
commercial kit to measure the level of p-S6RP as a biomarker of therapy with 
mTORIs  
3. Investigating the frequency and influence of seven relevant SNPs on Tac 
pharmacokinetics early after transplantation in a cohort of 121 renal transplant 
recipients.  
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3 Materials, patients and methods 
3.1 Materials 
3.1.1 Reagents  
Reagent  Supplier  
Phorbol 12-Myristate 13-Acetate (PMA) Sigma-Aldrich, Munich, Germany 
Ionomycin AppliChem GmbH, Darmstadt, Germany 
Cyclosporine A Sigma-Aldrich, Munich, Germany 
Tacrolimus Sigma-Aldrich, Munich, Germany 
Everolimus  Sigma-Aldrich, Munich, Germany 
Mycophenolic acid Sigma-Aldrich, Munich, Germany 
2 Mercapto-ethanol Merck, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Munich, Germany 
Fetal Calf Serum (FCS) PAN Biotech GmbH, Aidenbach, Germany  
Penicillin/Streptomycin(10,000 U/mL) Life Technologies, Paisley, UK 
Hepes buffer Life Technologies, Paisley, UK 
L- glutamine Life Technologies, Paisley, UK 
Bovine serum albumin (BSA) VWR International GmbH, Darmstadt, Germany  
Phosphate-Buffered Saline (PBS) Life Technologies, Paisley, UK 
RPMI 1640 medium Life Technologies, Paisley, UK 
ACK (Ammonium-Chloride-Potassium) lysing 
buffer 
Life Technologies, Paisley, UK 
RNaseOUT Invitrogen, Darmstadt, Germany 
High Pure RNA Isolation Kit Roche Diagnostics GmbH, Mannheim-Germany 
1st Strand cDNA Kit for RT-PCR (AMV) Roche Diagnostics GmbH, Mannheim-Germany 
LightCycler FastStart DNA Master SGI  Roche Diagnostics GmbH, Mannheim-Germany 
Primer set (Cyclosporine Immunemonitoring)  Search-LC, Heidelberg, Germany 
PerFix-p Kit Beckman Coulter, Marseille, France 
CD3-PC7  Beckman Coulter, Brea, CA, USA 
CD4-ECD Beckman Coulter, Brea, CA, USA 
CD8-PC5 Beckman Coulter, Brea, CA, USA 
Rabbit IgG Isotype Control Alexa Fluor® 488 
Conjugate 
Beckman Coulter, Brea, CA, USA 
Phospho-S6 Ribosomal Protein (Ser235/236) 
Alexa Fluor® 488 
Beckman Coulter, Brea, CA, USA 
QIAamp DNA Blood Mini Kit Qiagen, Hilden, Germany 
TaqMan Genotyping Assay Mix Thermo Fischer Scientific, Darmstadt, Germany 
TaqMan Universal PCR Master Mix Thermo Fischer Scientific, Darmstadt, Germany 
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3.1.2 Buffers and solutions  
Name Constituents Concentration 
Culture medium RPMI 1640 Medium 
Inactivated FCS  
Penicillin / Streptomycin  
Hepes buffer 1 M 
L Glutamine 200 mM 
β-mercaptoethanol (BME) in medium: : 50 ml of RPMI 
Medium + 35 µl BME 
500 ml 
50 ml 
5 ml 
5 ml  
5 ml 
2.5 ml 
Wash buffer 2% Phosphate-buffered saline  
Bovine serum albumin 
500 ml 
10 g 
3.1.3 Equipment 
Instrument  Supplier  
PP  tubes natur 12 ml 16/100 mm Hain Lifescience GmbH, Nehren, Germany 
PS Tubes 5 ml Greiner Bio-One GmbH, Kremsmünster, Austria 
Tube 50ml, 115x28mm, PP Sarstedt AG & Co, Nümbrecht, Germany 
Safe-lock tubes 1.5ml Eppendorf AG, Hamburg, Germany 
Multiply-Pro cup 0.2ml, PP Sarstedt AG & Co, Nümbrecht, Germany 
Pipettes (2µl, 10 µl, 100µl, 200µl, 1000µl)  Mettler-Toledo GmbH, Gießen, Germany 
Multichannel Pipette  Mettler-Toledo GmbH, Gießen, Germany 
Pipettes (10 µl, 100 µl, 1000 µl) Eppendorf AG, Hamburg, Germany 
Biosphere Filter Tips 10 µl  Sarstedt AG & Co, Nümbrecht, Germany 
SafeSeal-Tips (100 µl, 1 ml) Biozym Scientific GmbH, Oldendorf, Germany 
Serological pipettes 5ml, 10ml Greiner Bio-One GmbH, Kremsmünster, Austria 
Rubber pipette filler  Sigma-Aldrich, Munich, Germany 
Eppendorf 5417C Centrifuge  Eppendorf, Hamburg, Germany 
Universal 320 R benchtop centrifuge Hettich GmbH & Co. KG, Tuttlingen, Germany 
Hettich MIKRO 20 centrifuge Hettich GmbH & Co. KG, Tuttlingen, Germany 
Universal 16R centrifuge Hettich GmbH & Co. KG, Tuttlingen, Germany 
REAX 2000 vortex Heidolph GmbH & Co. KG, Schwabach, Germany 
Julabo R5 water bath   Julabo GmbH, Seelbach, Germany 
Mini galaxy A CO2 incubator RS Biotech Inc., Irvine, UK 
96-well Plate, Thermo-Fast®  Abgene, Hamburg, Germany 
384-well plate, Thermo-Fast® Abgene, Hamburg, Germany 
Veriti 384-well Thermal Cycler Thermo Fischer Scientific, Darmstadt, Germany 
ABI PRISM 7900HT Real-Time PCR System 
(TaqMan) 
Thermo Fischer Scientific, Darmstadt, Germany 
Nanodrop 2000c Peqlab Biotechnology GmbH, Erlangen, Germany 
LightCycler Capillaries (20 µl) Roche Diagnostics GmbH, Mannheim-Germany 
Primus 25 advanced thermal cycler peQlab, Erlangen, Germany 
LightCycler 2.0 instrument  Roche Diagnostics GmbH, Mannheim-Germany 
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Cytomics FC 500 Flow cytometer  Beckman Coulter GmbH, Krefeld, Germany 
 
3.1.4 Software and web servers 
Name Supplier  
ABI 7900HT v 2.4 Applied Biosystems (California, USA) 
R-3.2.3  www.r-project.org 
GraphPad Prism version 5.00 GraphPad Software, San Diego California, USA 
MedCalc Version 14.12.0. MedCalc Software, Ostend, Belgium 
Microsoft Excel Worksheet (2007) Microsoft Corp., Redmond, USA 
PubMed  http://www.ncbi.nlm.nih.gov/pubmed 
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3.2 Patients and methods  
3.2.1 NFAT-regulated gene expression assay 
A protocol for the analysis of the expression of the NFAT-regulated genes has been 
established in Heidelberg by Giese et al. (Giese et al., 2004) and a primer set for 
amplification of the target genes is commercially available (Search-LC, Heidelberg). The 
analytical performance of the assay was tested at the laboratory of Klinikum Stuttgart and an 
interlaboratory comparison with the renal transplant center in Heidelberg was conducted. The 
readout of the assay is the residual gene expression (RGE) which is the ratio of the expression 
level before and after drug intake.  
3.2.1.1 Patients 
Experiments were approved by the ethics committee of the Eberhard-Karls-University 
Tübingen. The analytical verification of the assay at the laboratory of Klinikum Stuttgart was 
done in vitro with anonymized drug-free left over whole blood samples which were spiked 
with Tac. For the inter-laboratory comparison of the assay, heparinized blood samples from 
10 patients under CsA therapy were compared. The samples were collected and analyzed in 
Heidelberg and then sent to the laboratory of Klinikum Stuttgart to be re-analyzed within 24 
hours.  
3.2.1.2 Methods 
3.2.1.2.1 Sample processing  
Sample processing was performed essentially according to the previously published protocol. 
A stimulation solution was prepared consisting of PMA (100 ng/ml) and ionomycin (5 µg/ml) 
in complete culture medium (RPMI-1640). To activate lymphocytes, 1 ml heparinized whole 
blood was pipetted into polypropylene plastic tubes and was incubated with 1ml stimulation 
solution at 37°C in a CO2 incubator (with 7% CO2) for 3 hours. RBCs were then lysed using 
Ammonium-Chloride-Potassium (ACK) lysing buffer. Total RNA was extracted with High 
Pure RNA Isolation Kit (Roche Diagnostics GmbH, Mannheim-Germany) according to the 
manufacturer‟s instructions. The elution volume was 50 µl, to which 1µl RNaseOUT 
(InvitrogenTM) was added. RNA samples were frozen at -80° C until further processing. At 
the time of reverse transcription, RNA samples were allowed to thaw and from each sample a 
volume of 8.2 µl was used to synthesize cDNA using First Strand cDNA Synthesis Kit for 
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RT-PCR (Roche Diagnostics GmbH, Mannheim-Germany) utilizing avian myeloblastosis 
virus (AMV) reverse transcriptase and oligo-(dT) primer according to the protocol provided. 
Reverse transcription was done on Primus 25 advanced thermal cycler (peQlab, Erlangen, 
Germany). The generated cDNA was diluted with ultra-pure H2O to a final volume of 500ml 
and stored at -20° C until PCR analysis. Real-time PCR was carried out on the LightCycler 
2.0 instrument (Roche Diagnostics GmbH, Mannheim-Germany) using LightCycler FastStart 
DNA Master SYBR Green I (Roche Diagnostics GmbH, Mannheim-Germany) and the 
LightCycler - Primer Set; Cyclosporine Immune Monitoring (Search-LC, Heidelberg). 
Quantification cycle (Cq) values were determined by the Fit-Points Method and a baseline at -
0.6. 
In the original protocol, Giese et al. used MagNA Pure lysis buffer to lyse leucocytes and a 
MagNA Pure-LC device to isolate mRNA, and they did not add RNase out to the eluted RNA.  
For in vitro experiments, blood was spiked with the desired concentration of Tac prior to the 
stimulation step. Spiking of samples with the drug was done at 37° C and 7% CO2 for 30 min 
3.2.1.2.2 Testing the analytical performance 
The analytical performance of the NFAT-regulated gene expression assay has been tested in 
terms of concentration-effect relationship, precision (within- and between-run), limit of 
quantification and stability. An inter-laboratory comparison with the University Hospital 
Heidelberg has been also performed.  
i. Concentration-effect relationship: The effect of different concentrations of Tac on the 
expression of NFAT-regulated genes was determined. Heparin anti-coagulated drug 
free whole blood (5 ml) was used. The blood was divided into 5 plastic tubes (1 ml 
each) and each tube was spiked with a specific concentration of Tac while one tube 
was left untreated. The concentrations tested were 50µg/L, 25µg/L, 12.5µg/L and 
6.25µg/L of Tac. 
ii. Within-run precision: The within-run precision of the NFAT-regulated gene 
expression assay was tested at three different concentrations of Tac (50 µg/L, 25 µg/L, 
and 12.5 µg/L) using 3 blood samples from 3 different individuals. The blood was 
processed in a way that allowed 6 independent measurements of RGE of each blood 
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sample. Whole blood was divided into 12 plastic tubes. Six of the samples were spiked 
with Tac while the other 6 were left untreated. At the end of the stimulation step RNA 
was isolated from all samples in parallel and stored at -80°C. The next day, cDNA was 
synthesized and stored at -20° C. Finally, 6 consecutive runs of PCR (treated versus 
non-treated) were performed and RGE was determined. Mean, standard deviation and 
coefficient of variation were calculated (n=6). 
iii. Between-run precision: Evaluation of the between-run precision by investigating the 
same blood sample on six different days is inapplicable due to sample instability over 
this period of time. Thus the between-run precision was tested starting from the step of 
the isolated RNA. The between-run precision was also tested at 3 different Tac 
concentrations (50 µg/L, 25 µg/L, and 12.5 µg/L) using remaining RNA samples of 
previously processed blood stored at -80°C. RNA samples were allowed to thaw and 
were pooled. One pool formed from RNA of Tac treated blood (50 µg/L, 25 µg/L, or 
12.5 µg/L) and another pool from RNA of non-treated blood. These 2 pools of RNA 
were reverse transcribed 6 times on 6 different days and 6 PCR runs were done on 6 
different days in parallel to calculate RGE. The mean, standard deviation and 
coefficient of variation were calculated (n=6). 
iv. Limit of quantification (LOQ): To determine LOQ of the NFAT-regulated gene 
expression assay, blank cDNA samples were spiked with known concentrations of IL-
2, INF-γ and GM-CSF cDNA standards (LightCycler Primer Set kit, Search-LC). The 
number of cDNA copies in each sample was determined using qPCR. Serial dilutions 
of the standards were applied until reaching a number of copies that could not be 
detected anymore. The lowest number of copies that showed a CV ≤ 20% (n=6) was 
set to be the LOQ (Armbruster and Pry, 2008). 
v. Stability: To assess the stability of the samples, 3 anonymized left over blood samples 
from routine diagnostics free of Tac or CsA were used. Each sample was divided into 
2 aliquots. One aliquot was analyzed at the day of blood collection, where it was 
incubated with Tac in a concentration of 25 µg/L and further processed as previously 
described. The other portion was stored at room temperature and processed after 24 
hours like the first day and by applying the same concentration of Tac. The results 
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were then compared and the % differences between the measurements in both days 
were calculated. 
vi. Inter-laboratory comparison: For the inter-laboratory comparison of the NFAT-
regulated gene expression assay, heparinized blood samples from 10 patients under 
CsA therapy were compared. For each patient 2 whole blood samples were collected 
at the University Hospital Heidelberg, one sample before and another sample 2 hours 
after CsA intake. Patient samples were analyzed at the University Hospital Heidelberg 
for NFAT-regulated gene expression using the validated protocol of Giese et al. 
(Giese et al., 2004) and then the whole blood samples were sent to the laboratory of 
the Klinikum Stuttgart to be re-analyzed within 24 hours. Patients gave their informed 
consent to this biomarker study in Heidelberg. 
3.2.1.2.3 Calculation of mean residual gene expression (RGE)  
A calculation sheet provided by Search-LC GmbH was used to calculate the residual 
expression of the NFAT-regulated target genes after drug intake. This calculation included a 
beta actin standard and normalization to 2 reference genes (β-actin and cyclophilin B). Mean 
RGE of IL-2, INF-γ and GM-CSF represents the ratio between the expression level before 
and 2 hours after CsA intake (in case of patient samples) or the ratio between the expression 
levels in treated versus non-treated blood samples (in case of in vitro experiments).  
3.2.1.2.4 Statistical analysis 
Statistical analyses were done using Microsoft Excel Worksheet 2007 and MedCalc Version 
14.12.0. (MedCalc, Oostende, Belgium) The Spearman rank correlation coefficient test was 
utilized to determine the correlation between the measurements in the two laboratories. 
Passing-Bablok regression analysis was applied to calculate the agreement between the 
measurements in both laboratories. Method bias was also investigated using a Bland-Altman 
difference plot based on expression of differences as percentages. 
3.2.2 Phosphoflow assay of S6RP 
To measure the level of phosphorylation S6RP by flow cytometry, a commercial kit for 
fixation and permeabilization of the cells in the context of whole blood samples and anti-
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phospho Ser 235/236 antibody were employed. The following protocol is part of published 
work by our group (Abdel-Kahaar et al., 2016). 
3.2.2.1 Patients 
Anonymized left over immunosuppressant drug-free EDTA whole blood samples and residual 
EDTA whole blood samples containing immunosuppressive drugs were from the routine 
laboratory at the Klinikum Stuttgart. In addition, three volunteers took a single dose of 
everolimus (0.5 mg tablet) and blood was collected 1 and 3 hours afterwards. Approval from 
the local ethics committee of the Ärztekammer Stuttgart was obtained. Complete blood count 
and measurement of blood concentrations of immunosuppressive drugs were done as a part of 
the routine tests in our department. Immunosuppressants were determined by a validated LC-
MS/MS procedure (Valbuena et al, 2015). 
3.2.2.2 Methods 
3.2.2.2.1 Sample processing  
Aliquots of 100 µl whole blood were pipetted into round-bottomed test tubes (4 tubes for each 
patient) and placed in a 37ºC water bath for 10 min. The PMA and the blank solution, which 
served as negative control, were freshly prepared. To decrease assay imprecision, aliquots that 
received PMA were performed as a duplicate where the mean of p-S6RP from both 
measurement is to be finally used. Stimulation was performed for exactly 6 min with 150 
µg/L PMA before samples were fixed with 65 µl of the fixation buffer. After adding the 
fixation buffer, the tubes were vortex mixed and further incubated for 10 min. Then 1 ml lysis 
buffer was added, the tubes were vortexed again and placed again in the water bath at 37ºC 
for 15 min. After complete lysis of RBCs, the samples were washed twice through adding 
cold (4°C) wash buffer (2% BSA in PBS), centrifugation at 500 g for 4 min and discarding 
the supernatant. Then antibodies were added as an antibody mix containing PC7-conjugated 
anti CD3, ECD-conjugated anti CD4, PC5-conjugated anti CD8 and Alexa Fluor® 488 
conjugated anti p-S6RP (S235/S236). To one set of tubes anti p-S6RP was replaced with 
Rabbit IgG Isotype Control Alexa Fluor® 488. The tubes were incubated in the dark for 30 
min at room temperature then washed with 2 ml cold wash buffer and then resuspended in 
350 µl resuspension buffer. Fixation and permeabilization of the cells were done using a 
PerFix-p Kit according to the manufacturer‟s protocol. 
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3.2.2.2.2 Testing the analytical performance  
The following experiments have been performed:  
i. Concentration-effect relationship: anonymized left-over drug-free whole blood 
samples (n=2) were supplemented with varying concentrations of Evr and incubated 
for 30 min in a CO2 incubator with 7% CO2 at 37°C. The clinically relevant 
concentrations of 2.7 µg/L, 9.1 µg/L and 27.4 µg/L were tested. 
 
ii. Verification of the effect of Evr on p-S6RP in vivo: three healthy volunteers took a 
single dose of Evr (0.5 mg tablet) and blood was collected 1 h and 3 h afterwards for 
assessment of the p-S6RP.  
 
iii. Specificity: specificity of the assay was investigated in vitro and ex vivo  
In vitro: anonymized left-over drug-free blood samples (n=4) were supplemented with 
different immunosuppressive agents (other than mTORIs) at high concentrations. 
Therefore, blood was spiked with Tac (25 µg/L), CsA (500 µg/L) or MPA (25 mg/L) 
in separate aliquots, while one aliquot was left untreated to serve as a control.   
Ex vivo: To determine the specificity of S6RP phosphorylation as a biomarker of 
mTORIs PD effects in vivo, we examined phosphorylation of S6RP in left-over 
samples from kidney transplant recipients receiving Evr (n=20), Sir (n=12), Tac 
(n=12) or CsA (n=12); dialysis patients but not receiving immunosuppressants (n=5); 
and patients with inflammatory conditions indicated by an elevated C-reactive protein 
(CRP) concentration of >10 mg/L (n=5). The levels of p-S6RP in these groups were 
compared to the levels in a control group (n=10) that did not belong to one of the 
patient groups mentioned above or show any abnormalities in their laboratory results. 
 
iv. Within-run precision: To test within-run precision, 4 blood samples (2 drug free and 2 
containing Evr) were processed 5-6 times in parallel.  
 
v. Stability of the analyte p-S6RP: stability was tested using blood samples without 
immunosuppressive drugs (n=3), blood samples with Sir (n=2) and one blood sample 
with CsA (n=1). The samples were processed on the day of blood collection, and 
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aliquots from these samples were stored at room temperature for repeated analysis 
after 24 h 
 
vi. Method comparison: in a separate set of experiments, a method comparison between 
phosphoflow assay for p-S6RP and an established state-of-the-art western blot 
protocol for PD monitoring of mTORIs based on the determination of p-p70S6K was 
performed (Hartmann et al., 2005). For this comparison, anonymized left-over blood 
samples from RTx patients receiving Evr (n=7), Sir (n=2) or CsA (n=1) and healthy 
volunteers (n=5) were used. Blood samples were divided into two aliquots; one aliquot 
was used to measure the level of p-S6RP by phosphoflow cytometry, while PBMCs 
isolated from the second aliquot were stimulated with PMA for 30 min and stored at -
20°C before sending to a reference laboratory for western blot analysis. 
3.2.2.2.3 Flow cytometric analysis 
Samples were analyzed on a Cytomics FC500 flow cytometer (Beckman Coulter). 
Phosphorylation of S6RP was examined separately in CD3+CD4+ and CD3+CD8+ cells. We 
used the median S6RP phosphorylation (from the histogram of the flow cytometer) as a 
measure of fluorescence intensity and an index of median S6RP phosphorylation in stimulated 
cells versus median S6RP phosphorylation in unstimulated cells as a read out of the net effect 
of the drug on the phosphorylation status of S6RP in the cells of interest.  
3.2.2.2.4 Western blot analysis  
In a separate set of experiments and to verify the measured values with a conventional 
method, we compared the results of phosphoflow cytometry with western blot technique. 
Blood samples of subjects receiving mTORIs (n=15) were divided into 2 aliquots; one aliquot 
was used to measure the level of p-S6RP by phosphoflow cytometry in our laboratory while 
PBMC were isolated from the second aliquot and stimulated with PMA for 30 minutes and 
stored at - 20° C before they were sent to the University Hospital Ulm to be analyzed by 
Western blot. While we used anti p-S6RP (S235/S236) in the phosphoflow protocol, an anti-
phospho-p70S6 kinase (Thr389) antibody was employed in the western blot protocol. Western 
blot analysis was performed as previously described (Hartmann et al., 2005). 
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3.2.2.2.5 Statistical analysis 
Statistical analyses were done using Microsoft Excel Worksheet 2007 and MedCalc statistical 
software (Ostende, Belgium). Comparisons of blood samples from different patient groups 
were made using the Mann-Whitney U test. For method comparison Passing & Bablok 
regression was employed. A p value <0.05 was considered significant. 
3.2.3 Genotyping methods for pharmacogenetics   
Single nucleotide polymorphisms (SNPs) in the genes of CYP3A4, CYP3A5 and ABCB1 were 
investigated to be correlated with the Tac pharmacokinetics.  
3.2.3.1 Patients  
A cohort of 121 renal transplant patients who underwent transplantation between 2009 and 
2015 at Klinikum Stuttgart were invited to participate in this study. The study was approved 
by ethics committee of the Eberhard-Karls-University Tübingen and all participants gave 
written informed consent. The standard maintenance therapy after renal transplantation at 
Klinikum Stuttgart is a triple therapy of Tac, MPA and a corticosteroid. Tac therapy is started 
at the day of renal transplantation using a dosage of 0.1mg/kg/day and subsequently adjusted 
to achieve a pre-defined target trough blood Tac concentration of 6-8 µg/L in the first three 
months after transplantation and 4-6 µg/L thereafter. Drug concentrations and administered 
doses were retrospectively collected from patients‟ records at Klinikum Stuttgart at the first 2 
weeks after transplantation. Dose-adjusted trough concentrations per body weight were 
calculated for the C0 (µg/L) level. Tac blood concentrations were routinely measured by a 
validated LC-MS/MS procedure. Tac measurements were not always available for all patients 
at all time points. Delayed graft function was defined as the need for dialysis therapy within 
the first postoperative week.  
3.2.3.2 Methods 
3.2.3.2.1 Sample processing  
For preparation of the samples for genotyping, DNA was isolated from the whole blood 
samples using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the 
manufacturer‟s protocol. In summary, 200µl whole blood is mixed with 20µl QIAGEN 
protease and 200µl buffer AL in 1.5 ml microcentrifuge tube and incubated at 56°C for 10 
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min to allow for lysis of the cells. Then 200µl ethanol is added to the previous mixture and 
the whole volume is transferred to the QIAamp Mini spin column supported by 2ml collection 
tubes. Ethanol is added to ensure optimal binding of DNA to the QIAamp membrane.  The 
spin columns with the supporting tubes are centrifuged at 8000rpm for 1min. At this step the 
DNA will be adsorbed onto the QIAamp silica membrane while the rest will pass through. 
The collection tube containing the filtrate is discarded and the spin column is placed in a clean 
2ml collection tube. This is followed by 2 wash steps; the first with adding 500µl buffer AW1 
followed by centrifugation at 8000rpm for 1 min and the second wash step with adding 500µl 
buffer AW2 and centrifugation at 14.000 rpm for 3 min. DNA is then eluted in a clean 1.5ml 
microcentrifuge tube using 200 µl buffer AE. The spin column loaded with buffer AE is 
incubated for 5 min at room temperature to increase the DNA yield. The last step is to 
centrifuge the spin columns with the collecting tubes at 8000rpm for 1 min. to receive the 
eluted DNA in the clean collection tubes.  
Concentrations of nucleic acid samples were assessed using Nanodrop 2000c (Peqlab 
Biotechnology GmbH, Erlangen, Germany) 
3.2.3.2.2 Selection of polymorphisms for genotyping 
A literature search regarding relevant candidate genes which may explain interindividual 
variability of calcineurin pharmacokinetics resulted in three genes which are CYP3A4, 
CYP3A5 and ABCB1. The samples were genotyped for seven selected known SNPs in these 
genes for which previously functional consequences have been reported. Predesigned 
TaqMan allelic discrimination assays (ThermoFischer Scientific, Darmstadt, Germany) were 
used for genotyping of these variants  
Gene SNP rs Nr. Assay ID 
CYP3A4 CYP3A4*22 rs35599367 C__59013445_10 
CYP3A4 CYP3A4*1B rs2740574 C___1837671_50 
CYP3A5 CYP3A5*3 rs776746 C__26201809_30 
ABCB1 3435T>C rs1045642 C___7586657_20 
ABCB1 2677T>G rs2032582 C_11711720D_40 
ABCB1 2677T>A rs2032582 C_11711720C_30 
ABCB1 1236T>C rs1128503 C___7586662_10 
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3.2.3.2.3 Taqman genotyping 
The seven selected SNPs were genotyped using TaqMan allelic discrimination assays 
(Applied Biosystems, Darmstadt, Germany) as follows: Genomic DNA was placed in a 384-
well plate (Thermo-Fast® Abgene, Hamburg, Germany) so that the final amount of genomic 
DNA in each well was 10ng. The samples were allowed to completely dry down by 
evaporation at room temperature in a dark, amplicon-free location. Amplification was 
performed on Veriti®384-well Thermal Cycler (Applied Biosystems) in a final volume of 5µl 
containing 10ng dried genomic DNA, 2.5µl of 2X TaqMan® Universal PCR Master Mix 
(Applied Biosystems), 0.25µl of 20X TaqMan® Genotyping Assay Mix (Applied 
Biosystems) and 2.5µl of DNase-free water. After PCR amplification, an endpoint plate read 
was performed on ABI PRISM 7900HT Real-Time PCR System (Applied Biosystems).  
3.2.3.2.4 Statistical analysis 
All statistical analyses were performed with R-3.2.3 software (www.r-project.org). The 
differences in quantitative variables (Area under the curve; AUC, of dose-adjusted Tac levels 
and Tac dose) among individuals with different genotypes were investigated using Kruskal-
Wallis tests or Wilcoxon-Mann-Whitney tests as appropriate. Associations between each of 
the seven SNPs and delayed graft function or acute rejection were investigated by Fisher‟s 
exact test. Linear modeling was used to investigate the association between ABCB1 
haplotypes (based on rs1128503, rs2032582, rs1045642) and log-transformed AUC of dose 
adjusted as well as dose and weight adjusted Tac levels.  A P-value of less than 0.05 was 
considered statistically significant. 
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4 Results 
4.1 NFAT-regulated gene expression assay 
4.1.1 Concentration-effect relationship 
Tac decreased the expression of NFAT-regulated genes in a concentration-dependent manner. 
The measured RGE values were of 15%, 47%, 71%, and 89% when the spiked Tac 
concentrations were 50 µg/L, 25 µg/L, 12.5 µg/L, and 6.25 µg/L, respectively (Figure 4).  
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Figure 4: Effect of different concentrations of Tac on the expression of NFAT-regulated genes, in vitro (Single 
determinations). Tac= tarolimus 
4.1.2 Precision  
The results are illustrated in Table 4.  
Table 4: The within- and between-run imprecision expressed as coefficient of variation 
of the NFAT-regulated gene expression assay at 3 different concentrations of Tac. 
 Within-run precision Between-run precision 
 Tac concentration Tac concentration 
 50 µg/L 25 µg/L 12.5 µg/L 50 µg/L 25 µg/L 12.5 µg/L 
Mean RGE (n=6) 15.9 36.1 82.6 16.5 34.0 87.5 
SD 2.6 5.0 2.3 2.3 1.7 6.0 
CV (%) 16.3% 13.9% 2.8% 13.7% 4.9% 6.8% 
CV = coefficient of variation; RGE= residual gene expression; SD= standard deviation; Tac = tacrolimus  
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The within-run coefficient of variation tested at 3 different concentrations was < 17%. The 
within-run CVs represent the imprecision of the whole assay and not only the PCR step. The 
between-run coefficient of variation at 3 different concentrations was < 14%. The between-
run CVs reflect the imprecision of the reverse transcription and PCR steps. 
4.1.3 Limit of quantification (LOQ) 
The LOQ of the NFAT-regulated genes was below 200 copies per reaction (Table 5). 
Table 5: The Limit of quantification (LOQ) of NFAT-regulated genes 
cDNA Mean (n=6) SD CV (%) 
IL-2 194 22.1 11.4 
IFN-γ 154 23.5 15.2 
GM-CSF 131 17.5 13.4 
CV = coefficient of variation; GM-CSF = granulocyte macrophage colony stimulating factor; IFN-γ = interferon 
gamma; IL-2 = interleukin 2; SD= standard deviation  
4.1.4 Stability  
Regarding stability of the samples, the difference between RGE of the same samples (n=3) 
measured twice within 24 hours was in mean 6% (range -15% - +19%). Figure 5 shows the 
RGE after 24 hours as a % of the measurement at the first day.   
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Figure 5: Stability of the NFAT-regulated gene expression assay: the residual gene expression measured after 24 
h was expressed as % in relation to the RGE measured at the day of blood collection which was set to be 100% 
(n=3). 
4.1.5 Inter-laboratory comparison 
The agreement between the RGE for the 10 patients measured in the two laboratories is 
shown in Figure 6. The Passing-Bablok regression analysis showed no significant deviation 
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from linearity. However, the regression line was tilted and no constant bias was observed over 
the measuring range. Low RGE values were higher in the Stuttgart lab and higher RGE values 
were lower in the Stuttgart lab compared to Heidelberg lab. However, this lead to an 
acceptable mean difference of 4.5 % when data from both laboratories were analyzed using a 
Bland-Altman method comparison plot. Spearman‟s rank correlation analysis revealed an 
excellent and highly significant overall correlation (r=0.951; p<0.0001, n=10). 
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Figure 6: Passing-Bablok regression analysis of residual gene expression (RGE) measured in Heidelberg and 
RGE measured in Stuttgart. Regression line (solid line), the confidence interval for the regression line (dashed 
lines) and identity line (x=y, dotted line) are displayed 
4.2 Phosphoflow assay of S6RP 
4.2.1 Concentration effect relationship 
Evr decreased the level of phosphorylation of S6RP in both CD3+CD4+ and CD3+CD8+ 
cells in vitro in a concentration-dependent manner as indicated in Figure 7. 
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Figure 7: Effect of different everolimus (Evr) concentrations on p-S6RP in CD3+CD4+ cells (A) and 
CD3+CD8+ cells (B). The level of p-S6RP at each concentration of Evr was expressed as % of the p-S6RP at 
control sample (drug-free) which was set to be 100%. This Figure was obtained from the published work of our 
group (Abdel-Kahaar et al., 2016) 
4.2.2 Verification of the in vivo effect of a single dose of Evr on p-S6RP 
Figure 8 indicates the changes in the level of S6RP phosphorylation in CD3+CD4+ and 
CD3+CD8+ cells at 1 and 3 h after a single dose of Evr (0.5 mg) in 3 healthy individuals. It 
can be seen that S6RP showed the greatest suppression at a time point that corresponds to the 
highest Evr concentration. 
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Figure 8: Time course of the effect of a single dose of everolimus (Evr) on the level of phosphorylation of S6RP 
in CD4+ and CD8+ cells and the concentration of Evr in blood. This Figure was obtained from the published 
work of our group (Abdel-Kahaar et al., 2016) 
4.2.3 Specificity 
Specificity of the assay was investigated using samples spiked with different 
immunosuppressants and using samples from various patient groups, including RTx patients 
treated with Evr and Sir. 
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 In vitro 
High concentrations of non-mTORI immunosuppressants fail to elicit a significant effect on 
the level of p-S6RP in vitro when compared to the controls, except for CsA in CD3+CD8+ 
cells (Figure 9) 
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Figure 9: In vitro effect of tacrolimus (Tac), cyclosporine A (CsA) and mycophenolic acid (MPA) on inhibition 
of S6RP phosphorylation in CD3+CD4+ cells and CD3+CD8+ cells. Controls did not contain 
immunosuppressants. Columns show median, and bars show 25th and 75th percentiles (n=4). Median of control 
= 100%, *=p<0.05. This Figure was obtained from the published work of our group (Abdel-Kahaar et al., 2016) 
 Ex vivo 
The results are illustrated in Figure 10.  
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Figure 10: Level of phosphorylation of S6RP (ratio of stimulated versus unstimulated) in CD3+CD4+ cells and 
CD3+CD8+ cells in different patient groups (horizontal lines show median and inter-quartile range). C = 
controls; Sir = sirolimus; CsA = cyclosporine A; Evr = everolimus; Infl. = Inflammation (CRP>10mg/L); Tac = 
tacrolimus; p-S6RP = phosphorylated S6 ribosomal protein. This Figure was obtained from the published work 
of our group (Abdel-Kahaar et al., 2016) 
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In comparison to the control group, the median p-S6RP was lower in both cell subsets in 
trough samples from patients who were under therapy with Evr or Sir. Statistical analyses 
showed a significant decrease in phosphorylation of S6RP only in CD3+CD8+ cells in the 
samples with Sir when compared to the control group (p=0.02). The differences between the 
other patient groups and the control group in both cell subsets were not significant (p>0.05).  
4.2.4 Within-run im precision 
The assay imprecision was ≤17% in 2 blood samples containing Evr in both CD3+CD4+ and 
CD3+CD8+ cells. Using 2 blood samples from healthy controls without use of 
immunosuppressant, the imprecision was ≤27% in both cell subsets (Table 6). The level of 
phosphorylation of p-S6RP is represented as the ratio of stimulated versus non-stimulated)  
Table 6: Within-run precision of the phosphoflow assay of S6RP in CD4+ (a) and CD8+ 
(b) cells. 
a) Imprecision of phosphoflow assay of p-S6RP in CD3+CD4+ cells 
 P-S6RP (mean)  SD CV%  
Healthy control (n=6) 73  19.3 26,4 
Healthy control (n=6) 63  14.1 22,2 
Patient sample (Evr treated) (n=6)  59  9,5 16,0 
Patient sample (Evr treated) (n=5) 75  9,4 12,5 
 
b) Imprecision of the phosphoflow assay of p-S6RP in CD3+CD8+ cells 
 P-S6RP (mean)  SD CV%  
Healthy control (n=6) 82 21,8 26,7 
Healthy control (n=6) 83 15,2 18,4 
Patient sample (Evr treated) (n=6)  73 12,7 17,4 
Patient sample (Evr treated) (n=5) 98  15,8 16,2 
CV = coefficient of variation; p-S6RP = phosphorylated S6 ribosomal protein; SD = standard deviation  
4.2.5 Stability 
Although some samples were stable after storage at room temperature for 24 h, other samples 
showed a steep fall in the level of p-S6RP phosphorylation (Figure 11). The difference 
between S6RP phosphorylation measured within 24 h after storage of the samples at room 
temperature (n=7) showed significant differences with (e.g. decrease of 67% or increase of 
32%). Based on these results, all other experiments were performed within 4 h of blood 
collection. 
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Figure 11: Change in p-S6RP phosphorylation in CD3+CD4+ cells and CD3+CD8+ cells after storage of the 
samples for 24 hours at room temperature. HC= healthy control; Sir = sirolimus-treated patient; CsA = 
cyclosporine A-treated patient; p-S6RP = phosphorylated S6 ribosomal protein. This figure was obtained from 
the published work of our group (Abdel-Kahaar et al., 2016) 
4.2.6 Method comparison  
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Figure 12: Comparison of western blot (p-p70S6K) and phosphoflow (p-S6RP) results in CD3+CD4+ cells (A) 
and CD3+CD8+ cells (B). Scatter diagram with regression line, confidence interval for the regression line and 
the identity line. The phosphoflow assay and the western blot were performed as given in Material and Methods. 
This Figure was obtained from the published work of our group (Abdel-Kahaar et al., 2016) 
There was no significant correlation (p<0.05) between the level of p-S6RP measured by 
phosphoflow and the level of p-p70S6K measured by western blot in both cell subsets. 
Passing & Bablok regression analysis showed no agreement between the two different 
methods to assess the PD effect of mTORIs (Figure 12). 
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4.3 Effect of pharmacogenetics on Tac pharmacokinetics in the early 
period after renal transplantation 
4.3.1 Demographic characteristics of the study cohort 
A total of 121 renal transplant recipients were enrolled in this retrospective study. The 
demographic data of the study population are described in Table 7.  
Table 7: Demographic characteristics of the study cohort: 
N 121 
Sex of patients (male/female) 77 (64%)/44(36%) 
Age of patients (years, median/range) 55 (15 – 77) 
Weight (kg, median/range) 76 (42 – 118) 
Transplantation before dialysis (pre-emptive) 10 (8%) 
Re-transplantation 22 (18%) 
Living/deceased donor 52(43%)/69(57%) 
Induction therapy  
 Basiliximab 104 (86%) 
 Thymoglobulin 17 (14%) 
Age of donors (years, median/range) 56 (19 – 88) 
ABO incompatibility 15 (12%) 
HLA mismatches (A, B, DR, median/range) 3 (0 – 6) 
Panel reactive antibodies > 50% 20 (17%) 
Cold ischemia time (min, median/range) 467 (39 – 2113) 
Warm ischemia time (min, median/range) 45 (21 – 86) 
Underlying disease  
– Glomerulonephritis 27 (22%) 
– Polycystic kidneys, adult type 
(dominant) 
24 (20%) 
– Interstitial nephritis/pyelonephritis 7 (6%) 
– Etiology uncertain 36 (30%) 
– Others 27 (22%) 
 
4.3.2 Frequency of the studied SNPs in the study cohort  
The frequencies of the different alleles of the SNPs are shown in Table 8. Most of patients 
who carry the CYP3A4*22 allele were also CYP3A5 non-expressers, however there was no 
linkage disequilibrium between the two SNPs observed (D‟ =1, r2=0.004). In a similar way, 
most of the patients who carry the CYP3A4*1B were CYP3A5 expressers but they show high 
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degree of LD (D‟ =0.92, r2=0.69). The clustering of CYP3A4*1B and CYP3A4*22 carriers 
according to CYP3A5 status is shown in Table 9.  
Table 8: Genotype and allele frequencies of the studied SNPs in the study cohort: 
SNP Allele frequency (%) Genotype frequency (n, %) 
ABCB1 1236 C>T 
rs1128503 
C 57.4% CC 43 (35.5) 
T 42.6% CT 53 (43.8) 
  TT 25 (20.7) 
ABCB1 2677 G>T/A 
rs2032582 
G 57.85% GG 41 (33.9) 
T 40.5% GT/GA 58 (47.9) 
A 1.65% TT/TA  22 (18.2) 
ABCB1 3435 C>T 
rs1045642 
C 51.4% CC 35 (28.9) 
T 48.6% TC 54 (44.6) 
  TT  32 (26.4) 
CYP3A5*3 
rs776746 
C 91.1% CC 103 (85.1) 
T 8.9% TC 17 (14.1) 
  TT  1 (0.8) 
CYP3A4*1B 
rs2740574 
T 95.5% TT  110 (90.9) 
C 4.5% CT 11 (9.1) 
CYP3A4*22 
rs35599367 
G 95% GG  109 (90.1) 
A 5% GA 12 (9.9) 
 
Table 9: Clustering of CYP3A4*1B and CYP3A4*22 carriers according to CYP3A5 
status:  
CYP3A5 
CYP3A4*1B CYP3A4*22 
*1/*1 *1/*1B *1/*1 *1/*22 
Non-expressers 102 1 92 11 
Expressers 8 10 17 1 
4.3.3 Effect of genotypes on the dose-adjusted concentration of Tac  
As the Tac trough levels (C0) were not available every day for all patients, we could not 
assess the C0/dosage ratio for the different genotypes on a daily basis. Instead, we used the 
available trough levels to measure the area under the time-concentration curve (AUC) as a 
rough estimation of the exposure to Tac. In addition, we compared the firstly-measured Tac 
C0 levels between the various genotypes. The daily dosage of Tac was available for almost all 
patients in our cohort until the patient discharged from the hospital or until the 16
th
 day after 
transplantation. Table 10 indicates the number of patients with available Tac dosages at each 
day until day 16 after transplantation. 
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Table 10: Number of patients with available Tac dosages at each day of the follow-up 
period: 
Day N Day N 
Day1 121 Day 9 120 
Day2 121 Day 10 112 
Day3 121 Day 11 104 
Day4 121 Day 12 93 
Day5 121 Day 13 88 
Day6 121 Day 14 80 
Day7 120 Day 15 64 
Day8 120 Day 16 56 
 
The AUC of dosage and weight-adjusted Tac concentrations was significantly higher in 
patients who are homozygous for the variant allele CYP3A5*3.   This effect was persistent in 
the first two weeks after transplantation. Patients who carry the CYP3A4*22 variant allele 
showed also a significantly higher AUC of dosage and weight-adjusted Tac concentrations 
when considering the two week period (days 1-16) as well as the second week (days 8-14) but 
not the first week (days 1-7) after transplantation. SNPs of the ABCB1 genes (individual SNPs 
and the T-T-T haplotype) and the CYP3A4*1B allele did not show a significant effect on the 
AUC of dosage and weight-adjusted Tac concentrations in this period (Table 11; Figures 13, 
14, 15, 16). 
Table 11: Statistical significance of the correlation between genetic variants and the 
AUC of Tac levels (dosage and weight adjusted) 
Genetic variant 
 
Statistical Test 
 
Unadjusted p-value  
AUC of Tac level/dosage/weight 
Day 1-16 Day 1-7 Day 8-14 
ABCB1 1236 C>T  Kruskal-Wallis 0.65 0.516 0.432 
ABCB1 2677 T>G/A  
Mann–Whitney U test  
(A carriers vs others) 
0.138 0.574 0.0601 
ABCB1 3435 C>T  Kruskal-Wallis 0.488 0.85 0.172 
ABCB1 haplotype 
T-T-T versus non T-T-T  
Mann–Whitney U test  
 
0.823 0.605 0.933 
CYP3A5*3  
Mann–Whitney U test  
(CC vs CT&TT) 
0.0014 0.0018 0.0025 
CYP3A4*1B  Mann–Whitney U test 0.167 0.105 0.386 
CYP3A4*22   Mann–Whitney U test 0.045 0.284 0.008 
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Figure 13: Beanplots illustrating the AUC of dosage&weight-adjusted Tac levels versus time in the first week 
after transplantation (AUC1-7) for each of the investigated genetic variants. The individual measurements are 
shown as lines. The median for each group is shown by a thick black line; the overall median in a plot is shown 
as a dotted line. 
Results 
 
43 
 
Figure 14: Beanplots illustrating the AUC of dose&weight-adjusted Tac levels versus time in the second week 
after transplantation (AUC8-14) for each of the investigated genetic variations. The individual measurements are 
shown as lines. The median for each group is shown by a thick black line; the overall median in a plot is shown 
as a dotted line. 
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Figure 15: Beanplots illustrating the AUC of dose&weight-adjusted Tac levels versus time at days 0-16 after 
transplantation (AUC1-16) for each of the investigated genetic variations. The individual measurements are shown 
as lines. The median for each group is shown by a thick black line; the overall median in a plot is shown as a 
dotted line. 
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Figure 16: Beanplots illustrating the AUC of dose&weight-adjusted Tac levels versus time as well as the AUC 
of Tac dosage versus time during the first week, second week and at days 0-16 after transplantation (AUC1-7, 
AUC8-14, AUC1-16) for the ABCB1 haplotype (T-T-T) compared to the other genotypes. The individual 
measurements are shown as lines. The median for each group is shown by a thick black line; the overall median 
in a plot is shown as a dotted line. 
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4.3.4 Effect of genotypes on Tac-dose requirements  
The results are illustrated in figure 17. None of the selected ABCB1 SNPs showed a 
significant effect on the Tac dosage requirement in the first 2 weeks after transplantation. 
Patients who carry the CYP3A5*3/*3 genotype showed a significantly lower dose requirement 
(mg/kg/day) compared to those who carry at least one functional allele (CYP3A5*1) 
considering a 2 week period after transplantation. There was also a trend of significance 
toward a decreased dose requirement in patients who carry CYP3A4*22, again considering a 2 
week period after transplantation; the difference reached statistical significance only at day 10 
(p= 0.0258). A similar trend in the opposite direction was shown for patients who carry the 
CYP3A4*1B requiring higher dosages of Tac; only at day 12, 15 and 16 data reached 
statistical significance keeping in mind that Tac dosages were missing for some patients at 
day 15 and 16 who already were discharged from hospital.  
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Figure 17: Tac dose per body-weight (mg/kg/day) at days 0-16 after transplantation for all investigated genetic 
variants. The different genotype groups are marked by different colors. Diamonds represent medians of Tac 
dose/weight at the different days; shaded areas are defined by 25% and 75% quantiles. Tac= tacrolimus 
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4.3.5 Association between the different SNPs and clinical outcomes 
Delayed graft function (DGF; defined as the need for dialysis in the first week after surgery) 
was observed in 30 patients (25%). Acute rejection was observed in 21 patients (17%) of the 
study population. ABCB1 3435 C>T polymorphism was found to be associated with increased 
risk of DGF (P = 0.02). No other significant associations between the investigated SNPs and 
acute rejection or DGF were found. The estimated glomerular filtration rate (eGFR) measured 
at discharge of patients was not significantly different between the genotypes studied (Table 
12).  
Table 12: Association between the studied SNPs und clinical events in the early post-
transplant period  
Genetic variant 
Unadjusted p-value  
eGFR MDRD at 
discharge (ml/min) 
Delayed graft 
function (DGF) 
Acute 
rejection 
ABCB1 1236  0.811 0.707 0.905 
ABCB1 2677 T >G/A  0.907 0.571 0.538 
ABCB1 3435 C>T  0.198 0.023 0.533 
CYP3A5*3  0.076 0.147 0.515 
CYP3A4*1B  0.891 0.463 1 
CYP3A4*22   0.384 0.728 1 
eGFR MDRD = estimated glomerular filtration rate by The Modification of Diet in Renal Disease study equation  
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5 Discussion 
 
“If it were not for the great variability among individuals, medicine might as well be a 
science, not an art” Sir William Osler, 1892 
 
5.1 The use of biomarkers to complement therapeutic drug monitoring of 
immunosuppressive therapy  
The field of transplantation medicine has witnessed a great success in the last few decades. 
This success is attributed in large part to the use of highly efficient immunosuppressive 
protocols (Lechler et al., 2005). CNIs and mTORIs represent important components of all 
immunosuppressive protocols. The use of these agents requires careful monitoring because of 
their narrow therapeutic window (i.e. having little difference between toxic and therapeutic 
doses) and their unpredictable pharmacokinetics (Halloran, 2004). 
Currently, the PK monitoring (conventional TDM) is used to guide the therapy with these 
drugs where the concentration of the drug in the blood is used to adjust the dose. This 
approach is very valuable to prevent acute fluctuation of the drug level in the blood and 
consequently may contribute to avoid acute toxicity and/or rejection (Budde and Glander, 
2005). However, this approach is highly limited to determine the optimal starting dosage for 
each individual patient since it can be applied only after the drug therapy has been started. 
Moreover, the PK approach is of less value to optimize the dosage of immunosuppressants in 
the stable phase after renal transplantation. The ultimate goal of the conventional TDM is to 
achieve a blood concentration of the drug within a pre-defined therapeutic range. This range, 
however, has not been established yet for the stable phase after transplantation where the risk 
of rejection varies among individuals and is decreasing over time (Olbricht, 2012). 
It became increasingly clear in recent years that the success in the early phase of renal 
transplantation does not continue regarding long-term function and patient survival. Two 
factors are in particular responsible for this. Firstly, chronic rejection is so far uncontrollable 
and secondly long term side effects of immunosuppression cannot be predicted, such as 
nephrotoxicity, development of diabetes mellitus and cardiovascular diseases and the 
incidence of opportunistic infections & malignant neoplasms (Lechler et al., 2005). In order 
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to improve the long-term results in the future, many transplant centers adopt a new strategy 
through tapering the dosage of the immunosuppressive drug to minimize the toxicity profile 
without increasing the risk for short-term graft survival. However, this strategy requires an 
individual approach since different patients have a different risk profile. At present time, there 
is a lack of indicators which allow a reliable assessment of the immune status of the 
individual patients (Olbricht, 2012). 
In line with this background, optimization of immunosuppressive drug therapy through the 
PK approach alone is insufficient and should be complemented with a PD and PGx 
approaches by the use of appropriate and validated biomarkers (Wieland et al., 2012). In 
general, biomarkers that can be used to manage the immunosuppressive therapy after 
transplantation fall into 2 categories: a) drug specific biomarkers which reflect the specific 
pharmacological effect of an immunosuppressive agent and b) drug non-specific biomarkers 
which reflect the overall effect of drugs influencing the immune function (Shipkova, 2016) 
(Figure 18).  
 
Biomarkers to manage 
immunosuppression in 
transplant patients 
Drug specific 
biomarkers
Pharmacokinetic 
biomarkers 
Drug concentration 
AUCs
Pharmacodynamic 
biomarkers
Target enzyme activity
Target gene expression 
Pharmacogenetic 
biomarkers 
Drug metabolizing enzymes 
Drug transporters
Drug targets
Drug non-specific 
biomarkers 
Biomarkers of 
organ damage 
Biomarkers of 
immune response 
 
Figure 18: Types of biomarkers to manage therapy with immunosuppressive drugs after transplantation (Adapted 
from Shipkova, 2016) 
Several biomarkers have been proposed to track the general effect of immunosuppressive 
therapy on immune cells (drug non-specific biomarkers). The activation and proliferation of T 
lymphocytes (which play a central role in the rejection reaction and in the defense against 
infection) are frequently monitored in ex vivo models in which the cells are stimulated by 
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mitogens. T cell activation may be monitored by e.g. the expression of surface molecules on 
CD3+, CD4+ or CD8+ cells, measuring intracellular ATP concentration in CD4+ cells, 
tracking cytokine production by activated T-cells (ELISPOT assay; enzyme-linked 
immunosorbent spot assay) or through measuring the level of soluble CD30 (sCD30) which is 
produced and released in blood by activated T lymphocytes. Lymphocyte proliferation may 
be traced by monitoring DNA synthesis or the expression of genes which play a role in the 
regulation of the cell cycle such as PCNA (proliferating cell nuclear antigen) (Shipkova and 
Wieland, 2012). Another approach to assess the status of the immune system comprises the 
determination whether tolerance has been developed, which would allow minimization of 
immunosuppression. An indicator of a possible tolerance are regulatory T-cells (Tregs), 
which can be identified by typical surface markers using flow cytometry (CD4+ CD25+ 
CD127low/–) or by means of demethylated transcription factor FOXP3 protein (Su et al., 
2012). Only two of these biomarkers were approved to be used clinically and include 
Immuknow™ which is a functional immune assay to measures the increase in ATP 
production by activated T-lymphocytes and the AlloMap® which measure specific gene 
expression patterns to determine the risk of acute rejection in heart transplant recipients 
(Wieland et al., 2012). 
This work focused on drug-specific biomarkers (PD and PGx) which will complement the 
classical PK approach for the individualization of immunosuppressive therapy. Specific PD 
biomarkers include measuring target enzyme activity or target gene expression while PGx 
biomarkers comprise genetic variants of candidate genes which could impact drug disposition 
or response.  
Different biomarkers could have different roles in optimizing immunosuppressive therapy 
after transplantation. The potential of each biomarker category can be seen in Figure 19. The 
PGx profile of the patient would be helpful in drug selection and in determining the starting 
dose of the drug. PD biomarkers, on the other hand, would help to select for the right dose 
over time (Urtasun et al., 2008).  
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Figure 19: The potential roles of different biomarkers to individualize immunosuppressive drug therapy 
5.2 Validation of biomarker assays  
For a biomarker to be appropriate to be implemented into routine clinical practice, certain 
criteria must be fulfilled. The biomarker a) should be non-invasive, easily measurable and 
cost-effective; b) a short turn-around time should exist (the result should be available within 
24 h); c) a reliable assay with data from clinical trials should be available and d) the assay 
should demonstrate satisfactory analytical performance. The availability of an optimized 
assay kit that is commercially supplied is also of a great advantage when it comes to the 
routine diagnostics, as it prevents the impairment of the assay performance by confounding 
factors (Shipkova et al., 2016).  
Despite the great number of biomarker studies that have been published in recent years, most 
of these biomarker assays did not find their way into clinical practice because they are, with 
few exceptions, neither analytically validated according to international guidelines nor 
suitable due to their complicated nature for routine use. Furthermore many laboratory-
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developed techniques have not been cross validated between laboratories and the 
reproducibility of results between laboratories is questionable (Shipkova et al., 2016). 
In the era of personalized medicine and with the expected increase in the use of biomarkers as 
a crucial component of the strategy of personalized medicine, the health authorities start to 
provide guidelines and regulations for validation of biomarkers. According to the FDA, a 
valid biomarker assay is „a biomarker measured in an analytical test system with well-
established performance characteristics and for which there is an established scientific 
framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic, or 
clinical significance of the test results‟ (FDA: Guidance for Industry Pharmacogenomic 
Data Submissions, 2005). 
To foster the implementation of new biomarkers into routine practice, more effort needs to be 
exerted for the analytical validation of promising candidate biomarkers according to 
international guidelines. The validation of biomarker assays must include the entire path 
starting with selecting the proper sample matrix, pre-analytical aspects and analytical 
performance. However, the level of validation depends on the intended use of the assay and 
also on the assay characteristics and this is called “fit-for-purpose” validation. In general, the 
performance characteristics that should be covered through validation of biomarker assays 
include one or more of the following parameters: linearity, specificity, precision, accuracy, 
analytical sensitivity (limit of detection (LOD) or LOQ) robustness and stability (Landeck et 
al., 2016). 
A next step after the validation of the assay in one center is the harmonization and 
standardization of the results across laboratories. Different laboratories adopt different 
approaches for sample processing and data analyses of biomarker assays. This results in 
discrepancies of the generated results which consequently raises the question about the 
clinical validity of such assays. Consequently, harmonization of the results of biomarker 
assays across laboratories is an essential pre-requisite before their clinical implementation on 
a wide scale (Britten et al., 2008). 
The discrepancy of results generated from different laboratories is also a major challenge in 
case of PGx biomarkers. While some laboratories report significant effects of a certain SNP 
or haplotype on the pharmacokinetics or pharmacodynamics of drugs, other laboratories 
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report non-significant or sometimes contradictory results. To overcome such a problem, large 
multicenter trials are needed where uniform phenotypic conditions have to be applied in all 
participating centers (study population, treatment strategy , …etc) (de Jonge and Kuypers, 
2008). 
For a more effective approach toward the implementation of the PGx biomarker in the clinical 
settings, the dynamic relationship between the individual‟s genotype and phenotype should be 
also considered. The effect of genetic variation on the drug‟s response is changing and 
depends on several factors. From this perspective, the development of algorithms to 
incorporate the PGx data with other covariates together would have a higher predictive value 
than the mere consideration of a single marker (Schwab and Schaeffeler, 2012). A 
successful implementation of this approach can be seen by the anticoagulant drug warfarin 
where genotyping data of CYP2C9/VKORC1 were combined with other factors e.g. age, sex, 
body mass index … etc. to generate an equation which can be used for dose calculation in 
clinical routine (Schwab and Schaeffeler, 2011).  
In this work, two PD biomarker assays were analytically evaluated; 1) NFAT-regulated gene 
expression assay which is developed to monitor the therapy with CNIs. This assay was 
developed in Heidelberg by Giese et al (Giese et al., 2004). However, data about the 
performance of this assay in an independent laboratory as well as data about interlaboratory 
performance were lacking. Thus this assay was validated in the laboratory of Klinikum 
Stuttgart and a small harmonization trial with kidney center in Heidelberg was conducted as 
well; 2) Phosphoflow assay of S6RP: a protocol to measure the level of phosphorylation of 
S6RP using the new technique of phosphoflow was set up and the analytical performance of 
the assay was investigated. This assay was intended to be used as a PD biomarker of the 
mTORIs.  
In addition to these two PD assays, a retrospective PGx study was also conducted to assess 
the prevalence of seven SNPs in functional relevant candidate genes (CYPs and ABCB1) 
using a cohort of 121 renal transplant recipients in Stuttgart and to elucidate the impact of the 
selected SNPs  on Tac pharmacokinetics in the early period after transplantation. 
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5.3 NFAT-regulated gene expression assay 
Consistent with their extensive use as immunosuppressive agents after organ transplantation, 
the effectiveness of CNIs on immune functions has been thoroughly studied to find out 
suitable PD biomarkers of their response. The change in the expression of cytokine genes 
under the influence of CNI is a potentially useful PD biomarker and the quantitative analysis 
of this change using RT-PCR has proposed as a tool for this purpose (Giese, 2001).  
Through their inhibitory effect on the transcription factor NFAT, three genes were found to be 
chiefly downregulated by CNIs; IL-2, INF-γ and GM-CSF. An assay protocol to measure the 
level of transcription of these genes before and after CsA or Tac intake was set up based on 
RT-PCR. The ratio between expression before and after drug intake expressed as RGE can be 
used as readout of the effect of CNI.  
The correlation between the RGE and clinical events after transplantation, particularly 
infection and malignancy, has been demonstrated in different patient cohorts. Sommerer et al. 
have also proved the ability to taper the dosage of CsA in stable transplant patients without 
risking the graft function based on RGE (Sommerer et al., 2008). Data on the analytical 
performance of this assay in two independent laboratories were, however, lacking.  
In this study, the guidelines and recommendations for validation of methods that depend on 
quantitative Real-Time PCR (Bustin et al., 2009; Broeders et al., 2014; Sanders et al., 
2014) were applied to test the performance characteristics of a PD assay based on analysis of 
gene expression to monitor therapy with CNI. To test the analytical performance of the assay, 
drug free blood samples which were supplemented with Tac in vitro were used. To assess the 
comparability of the NFAT-regulated gene expression assay between laboratories, samples of 
transplant patients under CsA therapy were collected and analyzed in Heidelberg where the 
assay has been established and set up for many years and sent to Stuttgart to be re-analyzed 
within 24 hours. Results of the in vitro experiments showed that the NFAT-regulated gene 
expression assay is reproducible at acceptable limits both within-series as well as between-
series after supplementation with Tac. Previously published results showed that using RT-
PCR to measure cytokine gene expression is sensitive and precise with a between-run 
precision <20% as reported by Giese et al. (Giese, 2001; 2003), which was confirmed when 
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using this assay in the Stuttgart lab. The performance data have agreed also with published 
guidelines for validation of qualitative real-time PCR methods (Broeders et al., 2014). 
The samples were stable after 24h of storage at room temperature which is valuable in clinical 
situations. Inter-laboratory comparison using blood samples from kidney graft recipients 
showed an acceptable bias between both labs. Using a Bland-Altman plot to investigate 
method agreement the mean difference between both laboratories was only 4.5 %. However a 
trend for a difference has been noted which was not constant over the observed range of RGE. 
As it can be seen from the Passing-Bablok regression analysis at lower RGE the results were 
higher in Stuttgart, whereas at higher RGE results were lower compared to Heidelberg. 
According to the experiences in Heidelberg, 10 copies/µl can be easily achieved on the 
LightCycler instrument for all three genes (T. Giese, personal communication) whereas in 
Stuttgart the LOQ was between 100-200 copies per reaction which corresponds to 20-40 
copies/µl in our qPCR protocol. This may explain the discrepant results particularly at the low 
end of the RGE observed in the inter-laboratory comparison experiment. This trend could not 
be further verified or ruled out in this small comparison study due to the limited number of 
samples. Although this shift between low and high RGE had no major impact on the overall 
satisfactory method congruence, this emphasizes the requirement to carefully validate or 
verify the performance of sophisticated biomarker assays before implementing them in a 
clinical setting. 
Taken together the data shows for the first time that the relatively complex assay can be 
applied in different laboratories leading to comparable results. These results were obtained 
despite the modification of a critical step of the assay protocol which is RNA isolation. The 
laboratory in Stuttgart used another approach to isolate RNA to accommodate the assay 
procedures to its own instruments. An important factor for this positive result is certainly a 
centralized primer production and a well-developed and described assay procedure which is 
provided to the customers in the package insert of the primers. The comparability of results 
between laboratories could be further improved by manufacturing standards and stable quality 
control material for the intra-laboratory control of accuracy and precision as well as for 
providing samples for a proficiency testing scheme which can be used for external quality 
control. 
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The possibility of obtaining comparable results of biomarker assays among different 
laboratories by adoption of uniform procedures in the field of transplantation medicine has 
been proven by Ashoor et al. They have cross-validated an IFN-γ Elispot assay for measuring 
the T-cell alloreactivity in renal transplant recipients and showed that the implementation of 
standard operating procedure (SOP) regarding sample processing and data analyses has 
remarkably improved the reproducibility of the assay with an interlaboratory CV of about 
30% (Ashoor et al., 2013). This activity was done under the umbrella of the CTOT (Clinical 
Trials in Organ Transplantation) consortium which is an association of multiple transplant 
centers in North America deeply engaged in transplant-related biomarker development and 
standardization. Other successful examples of biomarker assay harmonization by the CTOT 
consortium are the establishment of a SOP for gene expression profiling (Keslar et., 2013) 
and the standardization of solid phase multiplex-bead arrays for detection of HLA-antibodies 
(Reed et al., 2013).  
As a further extension of the efforts to promote the harmonization of biomarker immune-
monitoring, the transplantation community launched recently a project called “Global Virtual 
Laboratory (GVL)”. The objective of this project is the establishment and the universal 
dissemination of assay protocols which allow reliable monitoring of the alloimmune response 
(Geissler et al., 2015). 
In a future perspective, the NFAT-regulated gene expression assay has a potential to be used 
in multicenter trials involving local laboratories. Under these conditions it is feasible that in 
an acceptable time frame clinical data from multicenter trials with different grafts and 
immunosuppressive regimens will be available to estimate the true diagnostic sensitivity and 
specificity of the assay as well as the specific cut off values for CsA and Tac to predict 
clinical events. In addition, the NFAT-regulated RGE assay fulfills criteria which make it 
likely that the assay may reach routine application. However, one drawback is the requirement 
to collect two samples per patient one before and one after drug intake. This procedure may 
be suitable for an in-patient application but is inconvenient for an outpatient setting. 
5.4 Phosphoflow assay of S6RP 
The response to mTORIs entails many changes at the molecular level. The p70 ribosomal 
protein S6 kinase (p70S6K) and its target the S6 ribosomal protein (S6RP) are consecutive 
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molecules in the signaling cascade downstream to mTOR (Figure 3). Inhibition of the kinase 
activity of mTOR by the mTORIs resulted in decreased level of phosphorylation of these 
molecules which suggest the level of phosphorylation as a potential biomarker for mTOR 
inhibiting drugs.  
Hartmann et al. were able to measure the level of phosphorylation of p70S6K by western blot 
and they observed a significant decrease in the level of phosphorylation of p70S6K in patients 
treated with Sir when compared with patients under non-mTORI immunosuppression or with 
healthy controls. The level of phosphorylation was also correlated with the incidence of acute 
rejection (Hartmann et al., 2005). The use of Western blot is, however, suitable for research 
purposes but not for routine use.  
Flow cytometry is a powerful analytical platform and it is superior to many of the 
conventional methods since it is sensitive, rapid and high-throughput (Krutzik et al., 2004). 
The development of antibodies against phosphoproteins together with protocols for fixation 
and permeabilization of the cells has enabled the utilization of flow cytometry for detection of 
phosphoproteins inside the cells; this is called phosphoflow (Krutzik and Nolan, 2003).  
In this work, the level of phosphorylation of S6RP was measured through a phosphoflow 
protocol employing a commercial kit for fixation and permeabilization of leucocytes in whole 
blood samples (PerFix-p Kit, Beckman Coulter, Inc.) and anti-human p-S6RP (S235/S236) as 
a phosphoantibody. The assay performance was tested both in vitro where blood samples 
were spiked with different immunosuppressive agents as well as with clinical patient samples. 
In addition three volunteers took a single dose of Evr and the level of p-S6RP and the drug 
concentration in blood were measured 1h and 3h thereafter. A method comparison with 
western blot assay employing an anti p-p70S6K was also conducted 
In vitro experiments showed that p-S6RP reflects the effect of Evr in CD4+ as well as CD8+ 
cells. This effect has been verified in vivo with 3 healthy volunteers took a single dose of Evr. 
It was shown that the lowest level of p-S6RP correspond to the peak concentration of Evr in 
blood (Figure 8). However, on testing the specificity of the assay in vitro through spiking 
blood samples with large concentrations of non-mTORI immunosuppressants, a significant 
effect of CsA to decrease S6RP in CD8+ cells has been observed (Figure 9). A similar 
observation has been also reported by other research groups (Hoerning et al., 2015; Wang 
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and Fan, 2015). This observation may reflect the complexity of the signaling network that 
involves activation of mTOR which could be modulated by several other signaling pathways 
(Abdel-Kahaar et al., 2016).   
Applying the assay to measure S6RP in blood samples from different patient groups showed 
that the level of phosphorylation of S6RP is decreased in both CD4+ and CD8+ cells in Sir 
and Evr treated patients groups. However, this effect was statistically significant only with Sir 
in CD8+ cells. This effect may be attributed to the differences in the physiochemical 
properties between Sir and Evr (which may lead to differences in their pharmacokinetics or 
pharmacodynamics) on one side and differences between CD4+ and CD8+ cells regarding 
their different profiles of signaling cascades on the other side (Abdel-Kahaar et al., 2016).   
While Sir is a naturally occurring macrolide, Evr was produced by adding a hydroxyethyl 
group at position 40 of Sir. Owing to this chemical modification, the PK properties of the 2 
drugs vary considerably. Compared to Sir, Evr is more polar and has a much shorter 
elimination half life (28 h compared to 62 h in mean) (Klawitter et al., 2015).  
“The role of mTOR signaling in regulation of proliferation and differentiation of T cells 
varies between CD4+ and CD8+ cells and may entail diverse mechanisms. Likewise, 
pharmacological inhibition of mTOR signaling may induce different responses in both cell 
subsets. High dose of rapamycin inhibits both complexes of mTOR (mTORC1 and mTORC2) 
in CD4+ cells but not in effector CD8+ cells where mTORC1 only is inhibited. Analysis of 
the functional markers of PBMC in liver transplant patients who receive Evr by 
polychromatic flow cytometry showed that CD4+ and CD8+ cells express different panels of 
markers upon activation with a superantigen which is another evidence on the differential 
response of CD4+ and CD8+ cells to mTOR inhibition” (Abdel-Kahaar et al., 2016).   
While the assay concept was verified both in vitro and in vivo, the results of inter-method 
comparison of the same samples were disappointing. Parallel measurements of the same 
samples with western blot revealed lack of agreement between results from both methods. 
However, it should be noted that western blot analysis was performed with anti-p-S6K 
(Thr389) phosphoantibody while our phosphoflow protocol employs an anti-p-S6RP 
(Ser235/236). 
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In summary, the phosphoflow assay of p-S6RP as a PD biomarker of mTORIs provides 
several advantages including the possibility to work with whole blood samples and its 
satisfactory analytical performance. However the assay turns to be non-specific to the effect 
of mTORIs which questions its fitness for purpose. Whether further optimization of the assay 
protocol would improve the diagnostic utility, still needs to be determined. 
5.5 Effect of pharmacogenetics on Tac pharmacokinetics in the early 
period after renal transplantation 
The early period post-transplant is very critical since it is associated with the highest 
incidence of graft dysfunction or rejection which was found to be attributed to non-optimal 
exposure to Tac (Staatz et al., 2001; Kuypers et al., 2010a).  There is also no role for TDM 
to determine the initial dosing of Tac. Therefore, the presence of indicators of patient‟s 
response to drugs would be of major help in dose optimization regarding this critical time 
(Abboudi and MacPhee, 2012). It is well known that for some examples genetic variation 
can account for up 95% of interindividual variability in drug effects and disposition. Most of 
these variations are related to drug metabolizing enzymes or transporting proteins (Evans and 
McLeod, 2003). In this study, the influences of seven SNPs in CYP3A4/5 and ABCB1 on Tac 
PK in the early period after transplantation were investigated. The studied SNPs include: 
CYP3A5*3, CYP3A4*22, CYP3A4*1B, and four SNPs in the ABCB1 gene (3435T>C, 
2677T>G/A and 1236T>C).  
The significant role of the CYP3A5*3 on the PK of Tac in the early period post-
transplantation was confirmed. The frequency of *3/*3 genotype (non-expressers) in the study 
cohort was about 85%; these patients showed an increased AUC compared to CYP3A5 
expressers. This effect was persistent when considering the first week (AUC1-7 days), the 
second week (AUC8-14 days) or the whole follow-up period (AUC1-16 days). In addition, non-
expressers required lower doses of Tac compared to expressers and the difference was 
statistically significant at all time points. After exclusion of re-transplant patients and patients 
who were on Tac therapy before the transplantation for any reason, the firstly-measured C0 of 
Tac in de novo renal transplant recipients (n=77) was significantly lower in expressers versus 
non-expressers (P = 0.00045). These results were in line with previously published results 
(Zhang X et al., 2005; Roy JN et al., 2006 and Gervasini G et al., 2012). 
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Recently, a newly discovered SNP in intron 6 of the CYP3A4 gene (CYP3A4*22, rs35599367) 
was found to be associated with a higher Tac C0 and a lower Tac dose requirement compared 
to homozygous wild type subjects early after transplantation (Elens et al., 2013a and Pallet 
et al., 2015). However, the effect of this SNP was not unequivocal. Some research groups 
reported an effect of this SNP on Tac dose requirement (Gijsen et al., 2013) while others did 
not find any effect of this SNP (Tavira et al., 2013).  
In our study cohort of 121 renal transplant recipients, the frequency of the CYP3A4*22 
carriers was about 10%. Patients who carry this allele required lower weight-adjusted doses of 
Tac than non-carriers, whereas the difference reached statistical significance only at day 10 
post transplantation. The firstly-measured Tac C0 level in de novo transplant recipients 
(n=77) was higher in CYP3A4*22 carriers (ranging from 4.6 to 24.4, median 9.7mg) versus 
non-carriers (ranging from 2.5 to 28, median 7.6mg), however the difference was not 
statistically significant. Although we observed a statistically-significant difference between 
the 2 genotypes regarding the AUC in the second week post-transplant (AUC8-14 days, p= 
0.0078), this result should be interpreted with caution because many patients were discharged 
from the hospital after the 10
th
 day post-operative (see Table 10) and only limited every day 
Tac C0 levels were available for patients who stayed longer.  
The CYP3A4*1B was described to be an increased-in-function allele as its presence has been 
linked to increased gene expression (Amirimani et al., 2003). The results of the study cohort 
support this hypothesis as patients who carry this polymorphism required higher dosages of 
Tac during the first two weeks post-transplant. However almost all patients who carry 
CYP3A4*1B (10 out of 11) were also CYP3A5 expressers and a high degree of LD was 
observed between the two SNPs. A similar finding has been reported by Gervasini et al. in a 
cohort of 103 renal transplant recipients (Gervasini et al., 2012).  
The majority of the previous studies failed to find an independent effect of ABCB1 individual 
SNPs or haplotypes on Tac PK. Still, there were few studies which showed differences in PK 
of Tac among different ABCB1 genotypes; however these results were not conclusive and 
could not be replicated (see Table 3, reviewed in Wolking et al., 2015). In line with these 
studies, no effect of ABCB1 individual SNPs or haplotypes on Tac PK in the present study 
cohort was found.  
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The incidence of DGF was higher among patients who carry the ABCB1 3435 C>T 
polymorphism and the difference was statistically significant (P= 0.02). This correlation was 
noticed despite the lack of a significant effect of this polymorphism on Tac exposure or dose 
requirements in the study cohort which may reflect a toxic effect of increased intracellular 
Tac rather than the whole Tac blood level. Similar results have been reported by Cattaneo et 
al. where they found that carriers of the T variant allele of either the ABCB1 3435 C>T or the 
2677 G>T/A polymorphisms had a three-fold risk for DGF in a cohort of CsA-treated renal 
transplant recipients (Cattaneo et al., 2009).  
This study is among the relatively few studies to investigate the impact of genetic variation 
especially the new CYP3A4*22 SNP on the PK of Tac early after transplantation. The most 
consistent effect in the cohort under study seems to be attributed to CYP3A5*3 and to a lesser 
extent to CYP3A34*22 while the impact of other SNPs  is uncertain. Yet this study has some 
limitations. The most significant limitation of this study is the missing Tac C0 at each time 
point which precluded the analysis of the differences between various genotypes in PK 
parameters on a daily basis. A second limitation is the sample size which is relatively small. 
This small sample size implies difficulties in analyzing SNPs with low frequencies. For 
instance we identified only 12 patients who carry the CYP3A4*22 polymorphism and almost 
all of them are CYP3A5 non-expressers, thus we were unable to investigate the impact of 
CYP3A4*22 among the CYP3A5 expressers.  
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6 Summary  
The development of pharmacodynamic and pharmacogenetic biomarkers to complement the 
currently used pharmacokinetic approach to optimize immunosuppressive therapy after organ 
transplantation remains an ongoing need in the field of transplantation medicine. Several 
biomarker studies have been published in the last few years however, only few biomarker 
assays found their way to clinical practice. This is due to lack of validation, cross validation 
and standardization of potential biomarker assays.   
This work entailed the analytical validation of two pharmacodynamic (PD) biomarker assays. 
These include “NFAT-regulated gene expression assay” to monitor therapy with calcineurin 
inhibitors and “phosphoflow assay of S6RP” to monitor therapy with mTOR inhibitors. 
Additionally, a retrospective pharmacogenetic study to investigate the frequency and the 
impact of seven SNPs in the genes of CYP450 and ABAB1 on tacrolimus pharmacokinetics 
early after transplantation in a cohort of 121 renal transplant recipients was also conducted.  
It was proven that the “NFAT regulated gene expression assay” can be set up with 
satisfactory analytical performance in a routine molecular biology laboratory. In a small inter-
laboratory comparison, it was noted that the results generated from both laboratories are well 
correlated (r=0.951) but showed an inconsistent bias depending on the magnitude of residual 
gene expression (RGE, the readout of the assay).This observation denotes the need for careful 
validation of the biomarker assays as well as the harmonization of their results across 
laboratories before their clinical implementation.  
Measurement of phosphorylation status of S6RP through a phosphoflow protocol based on a 
commercial kit and utilizing whole blood as sample matrix has been proved to be non-
sophisticated and performs analytically well. However, specificity and stability of the assay as 
well as the disagreement with western blot (based on anti-phospho p70S6 kinase) questions 
its fitness for purpose as a PD biomarker of therapy with mTORIs.  
In a retrospective pharmacogenetic study, the effect of the CYP3A5*3 polymorphism on Tac 
pharmacokinetics early after transplantation was validated in a cohort of 121 renal transplant 
recipients in Stuttgart. Most of the individuals in the study cohort (85%) were CYP3A5 non-
expressers (*3/*3) and showed increased exposure to Tac as well as decreased dose 
requirements in the first two weeks after transplantation. The frequency of the newly 
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discovered CYP3A4*22 SNP was about 10% in the study cohort which coincides with 
previously published results. Patients who carry this variant allele showed increased exposure 
as well as decreased dosage requirement of Tac.  
In conclusion, this work proved the possibility to establish biomarker assays for 
individualizing immunosuppression with a satisfactory analytical performance in routine 
clinical laboratory especially when optimized assay protocols are applied and particularly 
when these are in the form of test kits. The reproducibility of the results across laboratories 
requires, however, careful harmonization/standardization of the assay conditions. The 
determination of the CYP3A5*3 as well as CYP3A4*22 polymorphisms may help to optimize 
the initial Tac dose,. 
Future perspectives:  
To facilitate the implementation of biomarker assays in the routine diagnostics in the future, 
standardization of the pre-analytical aspects as well as the analytical procedures are required. 
The clinical usefulness of the assay should be then assessed in prospective clinical trials 
involving many centers.  
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7 Zusammenfassung  
Die Nierentransplantation (NTx) ist eine Standardtherapie für viele Patienten im Endstadium 
einer Nierenerkrankung, da sie zu einer niedrigeren Sterblichkeitsrate sowie verbesserter 
Lebensqualität im Vergleich zu Dialyseverfahren führt. Das Gebiet der 
Transplantationsmedizin  hat große Fortschritte in den letzten Jahrzehnten gemacht. Dieser 
Erfolg ist zu einem großen Teil auf die Anwendung effektiver immunsuppressiver Therapien 
zurückzuführen. Die Calcineurin-Inhibitoren (Ciclosporin und Tacrolimus) und mTOR-
Inhibitoren (Sirolimus und Everolimus) sind wichtige Komponenten der immunsuppressiven 
Therapie. Die Verwendung dieser Medikamente erfordert jedoch eine sorgfältige 
Überwachung der Patienten aufgrund ihres engen therapeutischen Bereichs und ihrer schlecht 
vorhersagbaren Pharmakokinetik.  
Augenblicklich wird die Therapie mit diesen Medikamenten durch ein pharmakokinetisches 
Therapeutisches Drug Monitoring (TDM) gesteuert, bei dem die Dosis anhand der 
Konzentration des Medikaments im Blut eingestellt wird. Dies ist sehr gut geeignet um akute 
Schwankung der Medikamentenkonzentration im Blut zu kontrollieren und folglich eine akute 
Toxizität oder Abstoßungsreaktion zu vermeiden. Das TDM kann jedoch nicht dazu 
verwendet werden,  um die optimale Anfangsdosis für jeden einzelnen Patienten zu 
bestimmen, da es erst nach Beginn der Arzneimitteltherapie erfolgt. Es ist auch weniger gut 
für die Anpassung der Dosis der Immunsuppressiva in der stabile Phase nach der 
Transplantation geeignet, um Langzeitnebenwirkungen zu minimieren.  
Vor diesem Hintergrund wird deutlich, dass eine Optimierung der immunsuppressiven 
Therapien allein durch den pharmakokinetischen Ansatz nicht ausreichend ist, sondern dies 
mit pharmakodynamischen und/oder pharmakogenetischen Ansätzen unter Verwendung 
geeigneter Biomarker ergänzt werden sollte. Während pharmakodynamische Biomarker mit 
pharmakologischen Effekten der Medikamente auf Zielmoleküle assoziiert sind, 
konzentrieren sich pharmakogenetische Untersuchungen hauptsächlich auf 
arzneimittelmetabolisierende Enzyme (z.B. Cytochrom P-450 Polymorphismen) und 
Arzneimitteltransporterproteine (z.B. Mutationen in Genen der Familie der ATP-Bindungs-
Kassetten-Transporter) und damit in der Folge auf pharmakokinetische Parameter. 
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Trotz der großen Anzahl von Biomarker-Studien, die in den letzten Jahren veröffentlicht 
wurden, fanden die meisten Biomarker-Assays ihren Weg in die klinische Praxis nicht, weil 
sie, mit wenigen Ausnahmen, weder nach internationalen Leitlinien analytisch validiert noch 
wegen ihres komplizierten Aufbaus für den Routineeinsatz geeignet sind. Außerdem wurde 
die Reproduzierbarkeit der Assays zwischen unterschiedlichen Labors meistens nicht getestet. 
Weitere Studien sind daher erforderlich, um die Routinetauglichkeit der Biomarker-Assays 
mit dem Potential für eine klinische Anwendung zu testen. 
Diese Arbeit umfasst die analytische Validierung von zwei pharmakodynamischen 
Biomarker-Assays: die „NFAT-regulierte Genexpression“ zur Überwachung der Therapie mit 
Calcineurin-Inhibitoren und den „Phosphoflow Assay von S6RP“ zur Überwachung der 
Therapie mit mTOR-Inhibitoren. Zusätzlich wurde eine retrospektive pharmakogenetische 
Studie durchgeführt, in der die Häufigkeit und die Auswirkungen von sieben Einzelnukleotid-
Polymorphismen (SNPs) in Kandidatengenen (CYP450 Enzyme und P-Glykoprotein) für 
Tacrolimus (Tac) in der ersten Phase nach der Transplantation in einer Kohorte von 121 
Patienten nach Nierentransplantation untersucht wurden.  
Bestimmung der NFAT-regulierten Gen-Expression: Eine quantitative Analyse der 
NFAT-regulierten Gene (IL-2, INF-γ und GM-CSF) wurde als neuer pharmakodynamischer 
Biomarker für die Überwachung der Therapie mit Calcineurininhibitoren untersucht. Die 
Verfügbarkeit eines kommerziellen Kits (Search LC, Heidelberg) und ein gut etabliertes 
Testprotokoll machen diesen Biomarker-Assay zum vielversprechenden Kandidaten für die 
klinische Routinediagnostik. Voraussetzungen für die Umsetzung des Assays in der 
Routinepraxis sind allerdings die analytische Robustheit und vergleichbare Ergebnisse 
zwischen verschiedenen Laboratorien. Daher wurde das ursprüngliche Protokoll vom Institut 
für Immunologie in Heidelberg im Institut für Laboratoriumsmedizin des Klinikum Stuttgarts 
etabliert und verifiziert und eine Vergleichsstudie zwischen beiden Laboren durchgeführt.  
Für die analytische Validierung des Assays wurden Vollblutproben von gesunden Probanden 
mit Tac in vitro inkubiert. Linearität, Präzision, die Bestimmungsgrenze sowie die Stabilität 
der Proben wurden untersucht. Für den Interlaborvergleich wurden Proben von Patienten 
unter Ciclosporintherapie zuerst in Heidelberg analysiert und dann in Stuttgart innerhalb von 
24 Stunden re-analysiert.  
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Tac verringerte die Expression der NFAT-regulierter Gene in vitro in einer 
konzentrationsabhängigen Weise mit einer „Residual Gene Expression“ (RGE, verbleibende 
Genexpression) von 15%, 47%, 71% und 89% jeweils für die Konzentrationen von 50 ug/L, 
25 ug/L, 12.5 ug/L und 6.25 ug/L Tac. Die Intra- und Inter-Assay-Variationskoeffizienten 
(CV%) bei drei verschiedenen Tac Konzentrationen (jeweils n = 6) lagen bei <17%. Die 
Bestimmungsgrenze lag jeweils bei 100 cDNA-Kopien per Reaktion für die IL-2-, INF-γ- und 
GM-CSF-Genexpression. Wiederholungsmessungen derselben Probe nach 24 Stunden 
(Stabilität) ergaben einen Unterschied in der RGE von ≤ 19% (n = 3). Obwohl der Interlabor-
Vergleich von Patientenproben gut (r = 0.951) korrelierte, zeigte die statistische Analyse 
einen inkonsistenten Unterschied in Abhängigkeit von der Größe der RGE. 
Daraus kann geschlossen werden, dass die Bestimmung der NFAT-regulierten Gen-
Expression mit einer zufriedenstellenden analytischen Zuverlässigkeit in einem 
molekularbiologischen Routinelabor etabliert werden kann und vergleichbare Ergebnisse 
zwischen den Laboratorien zeigt. Jedoch erfordert die klinische Anwendung dieses Assays in 
der Routinediagnostik als pharmakodynamischen Biomarker für die Therapie mit CNIs eine 
Harmonisierung zwischen Laboratorien. 
Messung der Phosphorylierung des S6RP durch Phospho-Flow: Das S6 ribosomal Protein 
(S6RP) wird als nachgelagerter Effekt der mTOR-Aktivierung phosphoryliert. Die mTOR-
Inhibitoren Sirolimus und Everolimus unterdrücken die Phosphorylierung des S6RP in 
Lymphozyten. Daher kann der Phosphorylierungszustand von S6RP (p-S6RP) als Biomarker 
für die mTOR Hemmung durch Sirolimus und Everolimus verwendet werden. In dieser 
Arbeit wurde die Anwendbarkeit eines durchflusszytometrischen Phospho-Flow-Assays für 
die Messung des p-S6RP getestet.  
Ein kommerzieller Kit (PerFix-p, Beckman-Coulter) wurde für die Fixierung und 
Permeabilisierung der Zellen in Vollblutproben nach initialer  Stimulation mit PMA (150 
µg/L, 6 min, 37°C) eingesetzt. p-S6RP wurde separat in CD3+ CD4+ und CD3+ CD8+ T-
Zellen unter Verwendung eines anti-Phospho-Ser 235/236 Antikörpers mit Hilfe der 
Durchflusszytometrie untersucht. Der Assay wurde sowohl in vivo als auch in vitro getestet. 
Spezifizität, Linearität, Unpräzision in der Serie und Stabilität wurden untersucht. Das 
Ausmaß der S6RP-Phophsporyliserung  wurde in Proben verschiedener Patientengruppen  
Zusammenfassung 
 
68 
 
gemessen und mit einer Kontrollgruppe verglichen. Ein Vergleich mit einer Western-Blot-
Analyse der phospho-p70S6 Kinase (Thr389), die als Referenzmethode angesehen werden 
kann, wurde darüber hinaus durchgeführt. 
Everolimus verringerte p-S6RP in vitro konzentrationsabhängig (bis 27.4 µg/L). Dieser Effekt 
wurde auch in vivo nach einer Einzeldosis von Everolimus bei gesunden Probanden bestätigt 
(n = 3). Allerdings wurde die Phosphorylierung des S6RP auch gehemmt, wenn das Vollblut 
in vitro mit 500 µg/L Ciclosporin versetzt wurde. Der Variationskoeffizient in der Serie des 
Assays betrug <18% bei Transplantationspatienten  und <27% bei gesunden Kontrollen für 
beide T-Zell-Populationen. Phospho-S6RP war von begrenzter Stabilität (<24 Stunden). 
Patienten, die mit mTOR-Inhibitoren behandelt wurden, zeigten niedrigere p-S6RP in beiden 
T-Zellpopulationen. Dies war jedoch nur für CD3+ CD8+ T-Zellen von Sirolimus-
behandelten Patienten statistisch signifkant (p = 0.02). Es wurde keine signifikante 
Korrelation zwischen dem Phosphoflow und der Western-Blot-Analyse  festgestellt. 
Aus diesen Ergebnissen lässt sich schließen, dass der Phosphoflow Assay von p-S6RP zwar 
mehrere Vorteile bietet, wie z.B. die Verwendung von Vollblut und eine befriedigende 
analytische Leistung. Allerdings deuten die Ergebnisse bezüglich Probenstabilität, Spezifität 
und Vergleichbarkeit zur Referenzmethode darauf hin, dass eine Verwendung für klinische 
Zwecke als pharmakodynamischer Biomarker für die bessere Steuerung der Therapie mit 
mTORIs zweifelhaft ist. Ob sich dies durch eine Weiterentwicklung und Optimierung des 
Assays verbessern lässt, bleibt zu prüfen.  
Effekt der Pharmakogenetik auf die Pharmakokinetik von Tac in der frühen Phase nach 
der Nierentransplantation: Genetische Varianten können in einem hohen Ausmaß eine 
große interindividuelle  Variabilität der Arzneimittelkonzentrationen in vivo bedingen mit 
Konsequenzen für die Arzneimittelwirkung. Die meisten dieser genetischen Varianten 
betreffen arzneimittelmetabolisierende oder -transportierende Proteine. In dieser Arbeit wurde 
der Einfluss von sieben SNPs in den Kandidatengenen CYP3A4 und CYP3A5 sowie dem 
ABCB1 Gen (kodiert für P-Glykoprotein) auf die Pharmakokinetik von Tac in der frühen 
Phase nach der Transplantation untersucht. Die untersuchten Allele sind CYP3A5*3, 
CYP3A4*22, CYP3A4 *1B sowie die genetischen Varianten in ABCB1 (3435T> C, 2677T> 
G/A und 1236T> C). 
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Insgesamt wurden 121 nierentransplantierte Patienten im Klinikum-Stuttgart in diese 
retrospektive Studie eingeschlossen. Ein entsprechendes  Ethikvotum für die Studie lag vor. 
Die Genotypisierung wurde mittels Alleldiskriminierung mit etablierten und validierten Real-
time PCR (TaqMan)-Assays am Dr. Margarete Fischer-Bosch-Institut für Klinische 
Pharmakologie in Stuttgart durchgeführt. Bei den Untersuchungen eines möglichen  Effektes 
des CYP3A5*3-Polymorphismus auf die Pharmakokinetik von Tac zeigte sich zuerst, dass die 
meisten der Individuen in der Studienkohorte  (85%) CYP3A5 homozygote “Non-Expresser“ 
(*3/*3) waren, die in Übereinstimmung mit der Hypothese eine erhöhte systemische 
Exposition von Tac sowie einen verringerten Dosisbedarf von Tac in den ersten beiden 
Wochen nach der Transplantation zeigten. Die Häufigkeit des kürzlich beschriebenen 
funktionell bedeutsamen CYP3A4*22 Allels betrug etwa 10% in der Studiengruppe, was 
veröffentlichten Ergebnissen übereinstimmt. Patienten, die diese Variante Allel tragen zeigten 
erhöhte Exposition sowie einen verringerten Dosisbedarf von Tac. Die untersuchten  
genetischen Varianten in ABCB1 zeigten keinen signifikanten Effekt auf die Pharmakokinetik 
von Tac.  
Zusammenfassend konnte basierend auf den Daten der vorliegenden Arbeit gezeigt werden, 
dass pharmakodynamische Biomarker-Assays zur Individualisierung der Immunsuppression  
mit einer zufriedenstellenden analytischen Leistungsfähigkeit im klinischen Routinelabor 
etabliert werden können, vor allem, wenn optimierte Testprotokolle verwendet werden und 
insbesondere, wenn die Assays in Form von Testkits verfügbar sind. Insgesamt erfordert die 
Reproduzierbarkeit der Ergebnisse zwischen unterschiedlichen Laboratorien jedoch eine 
sorgfältige Harmonisierung bzw.  Standardisierung der Testbedingungen. Die Bestimmung 
der CYP3A5*3- sowie CYP3A4*22 Polymorphismus kann helfen die initiale Tac-Dosis zu 
optimieren. 
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